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2. Abbreviations 
AP-1: activator protein 1 
ATP: adenosine triphosphate 
BMDC: bone marrow-derived dendritic cell 
Cap: capsid protein 
CARD: caspase activation and recruitment domain 
CARDIF: CARD adaptor inducing IFN-β 
cDC: conventional dendritic cell 
ConA: Concanavalin A 
CPE: cytopathogenic effect 
CSFV: classical swine fever virus 
CTL: cytotoxic T lymphocyte 
DAI: DNA-dependent activator of IFN-regulatory factor 
DExD/H: aspartate-glutamate-any amino acid-aspartate/histidine 
ds: double-stranded 
EAV: equine arteritis virus 
eIF2: eukaryotic initiation factor 2 
Flt3-L: Fms-related tyrosine kinase 3 ligand 
FMDV: foot and mouth disease virus 
GAG: glycosaminoglycan 
GAS: IFN-γ-activated site 
GDP: guanosine diphosphate 
GTP: guanosine triphosphate 
HDP: host defense peptide 
IFI16: IFN-inducible protein 16 
IFN: interferon 
IPS-1: IFN-β promoter stimulator-1 
IRF: interferon regulatory factor 
ISG: IFN-stimulated gene 
ISG15: IFN-stimulated protein of 15 kDa 
ISGF3: ISG factor 3 
ISRE: IFN-stimulated response elements 
JAK: Janus activated kinase 
LDV: lactate dehydrogenase-elevating virus 
LGP-2: laboratory of genetics and physiology-2 
LPS: lipopolysaccharide 
LRR: leucine-rich repeats 
LV: Lelystad virus 
MΦ: macrophage 
MAPK: mitogen-activated protein kinase 
MDA5: melanoma differentiation-associated protein 5 
MDM: monocyte-derived macrophage 
MoDC: monocyte-derived dendritic cell 
Mx: myxovirus resistance 
MyD88: myeloid differentiation primary-response 88 
NETs: neutrophils extracelluar traps 
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NIPC: natural IFN-producing cells 
NK: natural killer 
OAS: 2′, 5′-oligoadenylate synthetase 
ORF: open reading frame 
Ori: origin of replication 
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PAM: porcine alveolar macrophages 
PAMP: pathogen-associated molecular patterns 
PBMC: peripheral blood mononuclear cell 
PCV1: porcine circovirus type 1 
PCV2: porcine circovirus type 2 
PCVAD: porcine circovirus-associated disease 
PCVD: porcine circovirus disease 
pDC: plasmacytoid dendritic cell 
PG: protegrin 
PI3K: phosphatidylinositol 3-kinase 
PKR: protein kinase R 
PMWS: postweaning multisystemic wasting syndrome 
PMA: phorbol 12-mistrate 13-acetate 
PMAP: porcine myeloid antimicrobial peptide 
PMNC: polymorphonulcear cells 
PPV: porcine parvovirus 
PR-39: proline-arginine-rich 39-amino-acid peptide 
PRR: pattern recognition receptor 
PRRS: porcine reproductive and respiratory syndrome 
PRRSV: porcine reproductive and respiratory syndrome virus 
RCR: rolling-circle replication 
RIG-I: retinoic acid-inducible gene I  
RLR: RIG-I-like receptor 
RNaseL: ribonuclease L 
SHFV: simian hemorrhagic fever virus 
RTC: replication and transcription complex 
ss: single-stranded 
STAT: signal transducer and activator of transcription 
STING: stimulator of interferon genes 
TGEV: transmissible gastroenteritis virus 
Th1 cell: helper 1 T cell 
Th2 cell: helper 2 T cell 
TIR: Toll/IL-1R 
TLR: toll-like receptor 
TNF: tumor necrosis factor
TRIF: TIR-domain-containing adapter-inducing interferon-β 
TYK2: tyrosine kinase 2 
2-5A: 2’, 5’- oligoadenylates 
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3. Abstract 
Type I interferons (IFNs), mainly IFN-α/β play a crucial role in innate defense against viruses. In 
addition to their direct antiviral activity, type I IFNs have antitumoral and immunomodulatory effects. 
Although all cells are virtually able to induce IFN-α, the plasmacytoid dendritic cell (pDC) subset 
represents the ultimate producers of IFN-α as well as other proinflammatory cytokines. Due to the 
specific expression of TLR7 and TLR9 recognizing single-stranded (ss) RNA and unmethylated CpG 
motifs respectively, pDCs can secrete up to 1000 times more IFN-α than any cellular types. 
Additionally, it is well known that several cytokines including type I and II IFNs, Flt3-L, IL-4 and 
GM-CSF favor pDC-derived IFN-α responses to unmethylated CpG motifs. In a first step, we aimed to 
characterize and clarify the interactions of two porcine viruses with pDCs. The double-stranded DNA 
replicative forms of porcine circovirus type 2 (PCV2) were demonstrated to inhibit CpG-induced IFN-
α by pDCs. Our study showed that none of the cytokines known to enhance pDC responsiveness can 
counter-regulate the PCV2-mediated inhibition of IFN-α induced by CpG, albeit IFN-γ significantly 
reduced the level of inhibition. Interestingly, the presence of IFN-γ enabled pDCs to induce IFN-α to 
low doses of PCV2. We also noted that after DNase treatment, PCV2 preparations were still able to 
stimulate pDCs. These data suggest that encapsulated viral ssDNA promotes the induction of IFN-α in 
pDCs treated with IFN-γ whereas free DNA, presumably as double-stranded forms, was responsible 
for inhibiting pDC responses. Regarding PRRSV, it has been reported that North American isolates 
did not induce and even inhibited IFN-α response in pDCs. However, PRRSV infection was also 
shown to lead to an induction of IFN-α in the serum and in the lungs suggesting that certain cells are 
responsive to the virus. Contrasting to previous reports we found that numerous PRRSV isolates 
directly induced IFN-α in pDCs. This response was still observed after UV-inactivation of viruses and 
required TLR7 signaling. The inhibition of CpG-induced IFN-α was weak and strain dependent, again 
contrasting with a previous report. We also observed that IFN-γ and IL-4 enhanced IFN-α response to 
two prototype strains, VR-2332 and LVP23. In summary, we demonstrated that both PCV2 and 
PRRSV promote IFN-α secretion in pDCs in vitro suggesting that IFN-α detected in PCV2- or 
PRRSV-infected animal might originate from pDCs. On the other hand, PRRSV replication is 
restricted to the macrophage (MΦ) lineage. These innate immune cells represent a heterogeneous 
population which can be induce to “classical” (M1) and “alternative” (M2) activated MΦ acquiring 
inflammatory or “wound-healing” functional properties, respectively. Nonetheless, little is known 
about the effect of polarization into M1 or M2 and the susceptibility of these cells to PRRSV. Thus, 
we examined the impact of cytokine on MΦ polarization into M1 or M2. Infections of these cells by 
several PRRSV isolates enabled the discrimination of PRRSV isolate in a genotype- and virulence-
dependent manner in M1 and IFN-β-activated MΦ. In contrast, the expression of PRRSV nucleocapsid 
in M2 or inactivated MΦ was indistinguishable among the PRRSV isolates tested. In the last part of 
my Thesis, we investigated the influence of three synthetic porcine cathelicidin peptides for their 
ability to deliver nucleic acid to pDCs. We reported that all cathelicidins tested can complex and 
quickly deliver nucleic acids resulting in IFN-α induction. Moreover, we show that the typical α-
helical amphipathic conformation is required to mediate killing of bacteria but not for inducing IFN-α 
secretion by pDCs. Furthermore, we found that E.coli treated with one of these cathelicidins is able to 
induce significantly higher levels of IFN-α compared to a non-sense version of the peptide. These data 
suggest that cathelicidins could influence the immune response in a two-step process. First, these 
peptides target bacteria leading to cell lysis. In turn, cathelicidins form complexes and deliver 
extracellular microbial nucleic acids released into pDCs. These pDC-derived IFN-α responses could 
be of particular relevance in driving the adaptive immune responses against microbial infections. 
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4. Introduction 
 
4.1. Overview of the IFN system 
Defense mechanisms of vertebrates can be roughly divided into innate and adaptive immunity. Innate 
immunity represents the first line of host defense and is characterized by well-conserved mechanisms 
of pathogen recognition leading to a rapid inflammation and antiviral state induction. In contrast, 
adaptive immunity includes slow processes, which involves highly specific B and T cell-mediated 
immune responses. The innate immune reactions upon pathogen infection are dedicated to slow down 
viral and bacterial spreading in the host and prime cells from the adaptive immunity to mount an 
efficient immune response. Such responses are triggered by the recognition of pathogens through 
pattern recognition receptors (PRRs) in host cells. The repertoire of PRR is limited since they are 
expressed by a serial of germline-encoded genes, which is in contrast to the high specificity of 
recognition of acquired immunity receptors, involving complex processes of gene rearrangements. The 
fact that PRR do not require a wide spectrum of specificity is explained by recognition of common 
structures and components of pathogens termed pathogen-associated molecular patterns (PAMPs) 
which are often primordial for pathogen survival. One important feature of the immune system is to 
discriminate between self and non-self in order to combat potent harmful pathogens and at the same 
time avoid damages to the host. The innate immune system has evolved in a way that PRRs recognize 
structural component of pathogens. For nucleic acids, their localization in specific cellular 
compartments has a major impact on their stimulatory activity. The recognition of PAMPs induces 
signaling cascades, which will lead to the expression of cytokines and other innate mediators. 
Accordingly, interferons (IFNs) are critical cytokines, which are produced by cells exposed to viruses 
or bacteria. In the host cell, the IFNs are essentially induced by the recognition of microbial nucleic 
acid, even though other PAMPs can be involved but in to a lesser extent. The IFN family is crucial for 
a direct antiviral activity and share also antitumoral and immunomodulatory functions. Although all 
cell types can induce IFNs, the plasmacytoid dendritic cells (pDCs) represents the ultimate cell subset 
to produce type I IFNs and other proinflammatory cytokines. The pDCs may act as sentinels of the 
innate immune system and alert non- and immune cells in case of viral infections. 
 
4.1.1. IFN family 
After more than 50 years of the discovery of IFNs defined by their capacity to “interfere” with viral 
replication [1], intensive research in the field described these cytokines as a large family comprising 3 
major groups of cytokines referred as type I, II and III, type I known for being the largest with many 
subtypes within the group [2]. 
Type I IFN: 
The type I IFNs are the most well-characterized type and demonstrate antiviral and antitumoral 
activity as well as several immunomodulatory functions [3, 4]. They encompass several members 
including IFN-α, -β, -ω, -ε and -κ. Other IFN species such IFN-δ and –τ have been found in pig and 
sheep respectively [5, 6]. In mice, IFN-ζ (referred as limitin) has also been noted [7]. The most 
dominant type is represented by IFN-α, which comprises many subtypes, whereas only one has been 
reported for IFN-β in human and pig [2, 8]. All these members are induced by the recognition of 
PAMPs through PRRs including Toll-like receptors (TLRs), cytosolic retinoic acid-inducible gene I 
(RIG-I)-like receptors (RLRs) and cytosolic DNA sensors. The secreted type I IFNs can act both 
locally and systemically and signal through a heterodimeric IFNAR1 and IFNAR2 receptor in resting 
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cells. This will lead to the expression of several hundred IFN-stimulated genes (ISGs), which will 
participate in fighting against invading pathogens especially viruses and will modulate the adaptive 
immune responses [9, 10]. 
Type II IFN: 
Type II IFNs comprise only IFN-γ [11]. In contrast to type I IFNs, IFN-γ is not produced by virus-
infected cells but rather by activated natural killer (NK),  helper 1 T (Th1) and cytotoxic T cells [12]. 
In addition to its antiviral activity, type II IFN contributes to the induction of CD8+ cytotoxic T 
lymphocyte (CTL) and mount efficient responses against tumors [13]. This cytokine is also important 
to activate macrophages (MΦ) and mediate intracellular killing of pathogens [14]. Like for type I 
IFNs, IFN-γ is recognized by a receptor complex containing a pair of two subunits of IFNGR1 and 
IFNGR2 [15]. 
Type III IFN: 
Recently, a type III IFNs has been described comprising IFN-λ. This type III shows antiviral activity 
stimulating the expression of ISGs as the other type I IFN species do. Whilst IFN-λ interacts with a 
unique heterodimeric receptor complex composed of an IFN-λR1 chain and IL-10R2 chain, it activates 
the identical signal transduction pathway than type I IFN [16]. 
 
4.1.2. Induction of type I IFN by nucleic acids 
The induction of type I IFNs, especially IFN-α/β, has been well investigated in response to viruses. 
Since the discovery of TLRs, a battery of PRRs including RLRs and cytosolic sensors have been 
shown to bind to different nucleic acid molecules. When a cell is infected by viruses or bacteria, the 
foreign nucleic acids either in a single-stranded (ss) or double-stranded (ds) form of DNA or RNA can 
be exposed to the PRRs for the recognition by the host cells. Here, I will focus on PRRs recognizing 
nucleic acids because these molecules might be the most important PAMPs during viral infections. 
The family of TLRs includes several transmembrane proteins (10 in human) which share common 
domains including leucine-rich repeats (LRR) in the extracellular moiety and a Toll/IL-1R (TIR) 
domain in their cytoplasmic tail. The LRR ectodomain forms a horseshoe shape and contains two 
copies of 19-25 repeats of 24 to 29 amino acid sequences with typical leucine motifs [17]. Despite the 
fact that the LRR domains among TLRs are quite well conserved, the recognition of pathogens 
components is broad and diverse. Several types of nucleic acids including dsRNA (TLR3), ssRNA 
(TLR7 and TLR8) and DNA with unmethylated CpG motifs (TLR9) can be recognized [18-21]. These 
TLRs decorate endosomal compartments to avoid recognition of self nucleic acid molecules, which 
locate elsewhere in the host cells, such as in the nucleus or cytoplasm. Additionally, the other TLRs 
are expressed on the cell surface and interact with lipoproteins (heterodimers of TLR2 and TLR1 or -
6), lipopolysaccharide (LPS; TLR4) and flagellin (TLR5) [22]. Upon binding to PAMPs, the TIR 
domain of TLRs dimerizes causing a special alteration. This conformational change of the cytoplasmic 
region leads to the recruitment of TIR-domain-containing adapter proteins. Except for TLR3, all TLRs 
seem to be dependent on the myeloid differentiation primary-response 88 (MyD88) adaptor protein. 
For TLR3-activation, another adapter protein referred as TIR-domain-containing adapter-inducing 
interferon-β (TRIF) is involved to trigger the signaling cascade. Thus, two pathways for type I IFN 
induction have been described based on the differential expression of TLRs and adapter proteins [23]. 
MyD88-dependent pathway involved a phosphorylation cascade leading to the activation and 
translocation of interferon regulatory factors (IRF) 7 and IRF5, nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1) into the nucleus. Whilst IRFs 
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bind to the promoter of IFNA genes or ISGs, the transcription factors NF-κB and AP-1 mainly activate 
the transcription of proinflammatory cytokines such as IL-6 or tumor necrosis factor (TNF)-α. In some 
extent, NF-κB binds also to the promoter of IFNB1 gene, leading to the expression of IFN-β [24]. The 
TRIF-dependent pathway recruit different protein complexes than MyD88 adapter protein, however 
the signaling cascades converge partly to the translocation of IRF3 and NF-κB into the nucleus 
resulting in the initiation of IFNB1 and proinflammatory cytokine transcription respectively. 
Additionally, TLR4 triggering can induce TRIF-dependent signaling but the resulting production of 
IFN-β is induced by LPS instead of nucleic acids. The MyD88-dependent pathway is mainly 
associated to pDCs whereas TRIF-dependent pathway is characteristic of conventional dendritic cells 
(cDC) and MΦ [25-27]. 
While TLR3 is found to recognized poly(I:C) mimicking dsRNA molecules, transcriptional levels of 
IFN-α/β were not completely abolished in MΦ from TLR3-/- mice [18] indicating that other receptors 
must be involved. Further investigation by screening cDNA library demonstrated that RIG-I was 
responsible for sensing dsRNA in the cytosol in TLR3-independent manner [28]. This finding 
conducted to the discovery of other members of RLR family such as melanoma differentiation-
associated protein 5 (MDA5) and laboratory of genetics and physiology-2 (LGP-2) showing homology 
in their amino acid sequence [29]. The RLR members possess an aspartate-glutamate-any amino acid-
aspartate/histidine (DExD/H)-box region common to RNA helicases and a regulatory domain in the C-
terminal part. Additionally, RIG-I and MDA5 comprise two caspase activation and recruitment 
domains (CARD) in the N-terminal which enables the interaction with the adapter protein IFN-β 
promoter stimulator-1 (IPS-1) also known as CARD adaptor inducing IFN-β (CARDIF) important for 
downstream signaling [30, 31]. The final signaling events include the recruitment of IRF3 and NF-κB 
into the nucleus to activate the transcription of ISGs. While RIG-I and MDA5 have been found to 
recognized 5’-triphosphate replicative form of RNA viruses and long dsRNA respectively, it is not 
clear which motifs are essential for RLR binding to allow discrimination between self-RNA molecules 
[32]. Further investigation must be conducted to clarify the exact viral nucleic acid structure that is 
crucial for RLR recognition. 
Since the past few years, new classes of receptor regrouping diverse cytosolic DNA sensors have been 
identified. The first member, the DNA-dependent activator of IFN-regulatory factor (DAI) was found 
to bind to dsDNA in the cytosol and induce a signaling cascade, which ends with the translocation of 
IRF3 into the nucleus to express type I IFN genes [33]. The IFN-inducible protein 16 (IFI16) was also 
demonstrated to bind to dsDNA and induce type I IFNs [34]. The expression of type I IFNs through 
DAI or IFI16 depends on the adapter protein referred as to stimulator of interferon genes (STING) 
which is associated with reticulum endoplasmic [35]. While IFI16 signalization depends on IRF3, DAI 
recruits both IRF3 and NF-κB to induce the expression of type I IFN and proinflammatory cytokines 
respectively [36]. 
More recently, cytosolic DNA sensors belonging to the DExD/H-box RNA helicase family have been 
identified in pDCs. They are referred as DHX36 and DHX9 and bind to type-A and type-B CpG 
respectively. Both of them interact with MyD88 but only DHX36-driven signaling promote IRF7 
translocation and expression of type I IFNs. In contrast, DHX9 induces proinflammatory cytokines 
such as TNF-α by the activation of NF-κB [37]. 
It becomes clear that the type I IFN induction is finely regulated and depends on the cell types which 
differentially express certain PRRs. Ongoing research on network signaling improves our 
understanding of the type I IFN induction by nucleic acids and will clarify the exact role of individual 
PRR in the induction of innate immune reactions against self and non-self components [25, 26]. 
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4.1.3. Signaling pathways of type I IFN 
Type I IFNs bind to a single heterodimeric receptor comprising two subunits IFNAR1 and IFNAR2 
expressed by all cell lineages. Each subunit is associated with members of Janus activated kinase 
(JAK) family including tyrosine kinase 2 (TYK2) for IFNAR1 and JAK1 for IFNAR2. Upon binding 
to type I IFNs, dimerization of the receptor occurs and induces an auto-phosphorylation of the 
associated JAKs [38, 39]. 
So far, several pathways have been defined for the downstream signaling events but one referred as the 
“classical pathway” has been intensively characterized and involved signal transducer and activator of 
transcription (STAT) proteins. The activation of JAKs TYK2 and JAK1 lead to the phosphorylation 
and activation of STATs including STAT1, STAT2, STAT3 and STAT5. In turn, homo- or 
heterodimers of STATs are formed and translocate into the nucleus where they bind to the promoters 
of ISGs [40]. The STAT1 and STAT2 heterodimers can be also associated to IRF9 to constitute ISG 
factor 3 (ISGF3) complex. The complex ISGF3 acts as transcription factor and binds to specific DNA 
sequence of IFN-stimulated response elements (ISRE) located in some of promoters of ISGs. In 
addition to ISRE, other specific regions known as IFN-γ-activated site (GAS) can be recognized by 
several other STAT homo- or heterodimers promoting the transcription of another class of ISGs. 
Stated another way, the type I IFNs signal through a single IFNRA receptor leading to 
phosphorylation of STAT members by tyrosine kinases resulting in the expression of ISGs. 
It becomes clear that many activation combinations of STATs are induced according to the IFN 
subtype, leading to the specific expression of only certain ISGs. Additionally, others adapter proteins 
have been found to be activated by type I IFNs. These protein are part to the mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling cascades [41]. 
 
4.1.4. Effector functions 
The effects mediated by type I IFNs are characterized by antiviral, antitumoral and 
immunomodulatory activities including NK and Th1 cell activation [42], antigen cross-presentation by 
dendritic cells [43], as well as antibody production and isotype class switching in B cell [44]. On 
another hand, the cells exposed to type I IFNs possess an array of ISGs. These genes encodes for 
proteins, which operate as direct antiviral effectors. This includes the GTPase myxovirus resistance 
(Mx) proteins, the 2′, 5′-oligoadenylate synthetase (OAS)/ribonuclease L (RNaseL), the protein kinase 
R (PKR) and the IFN-stimulated protein of 15 kDa (ISG15) [9]. In this respect, many other proteins 
may contribute to the antiviral effects but their exact role is not clearly defined. 
The Mx proteins are the most characterized family of IFN-induced GTPases out of four. In human, 
only two members composed this class, MxA and MxB [45]. It was demonstrated that MxA confers 
resistance to several viruses [46, 47]. This protein has been shown to self-assemble and might interact 
with nucleocapsid-like viral proteins, trapping viral component to prevent replication [48]. 
Importantly, the MxA protein locates in the endoplasmic reticulum suggesting that the traffic between 
cellular compartments might be controlled and screened for viral components [49]. Thereby, early 
virus replication can be affected by the Mx proteins. 
The OAS proteins comprise a class of enzymes that are able synthesize 2’, 5’- oligoadenylates (2-5A) 
from adenosine triphosphate (ATP). Originally, 2-5A has been found to inhibit protein synthesis in a 
cell-free system [50]. This mechanism is now confirmed by the activation of RNaseL through 2-5A. 
Upon binding to 2-5A, RNaseL undergoes conformational changes [51], which leads to its activation 
and to the degradation of ssRNA molecules [52]. Moreover, OAS needs to recognize dsRNA to further 
catalyze ATP to 2-5A in the cytosol. With this duality, OAS protein can be considered as a PRR as 
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well as an effector protein. Consequently, OAS/RNaseL pathway represents a unique antiviral late 
phase system enabling the degradation of viral RNA in the infected host cells. 
PKR is a serine threonine kinase, which recognizes dsRNA and participates in many cellular 
processes. A first role was discovered in a cell-free system in which the translation was inhibited by 
this protein [53], a mechanism which have been so far clarified. When the dsRNA ligand binds to 
PKR, it autophosphorylates and following dimerization, activates the alpha subunit of eukaryotic 
initiation factor 2 (eIF2α) changing its conformation. The protein participates in the translation 
initiation with 40S ribosome and depends on guanosine triphosphate (GTP). Recycling of eIF2α 
requires eIF2B, which catalyzes eIF2α-guanosine diphosphate (GDP) to eIF2α-GTP. When eIF2α is 
phosphorylated by PKR, its higher affinity for eIF2B leads to sequestration, blocking the synthesis of 
eIF2α-GTP [54]. Consequently, PKR activation leads to the inhibition of the viral RNA translation. In 
addition, PKR also participates to apoptosis and activation of transcription factors such as NF-κB [55]. 
The ISG15 shares some homology with the ubiquitin protein, which is important in many cellular 
processes. In addition, ISG15 was found to be conjugated to several cellular proteins after exposure to 
type I IFNs [56]. The conjugation of ISG15 to certain proteins is termed as ISGylation and require a 
set of enzymes which is analogous to the ubiquitin modification system. It has been shown that 158 
potential targets can be associate to ISGylation [57]. Thus, ISG15 enables to control cellular processes 
by a similar mechanism which is observed during the ubiquitination [58]. 
 
4.1.5. Plasmacytoid dendritic cell subset 
Although all cell types can theoretically produce type I IFNs, the characterization of pDC subset 
demonstrated that these cells, also referred as natural IFN-producing cells (NIPC) are able to secrete 
200 to 1000 times more type I IFN than any other cells [59]. The remarkable capacity of pDCs to 
promptly respond to viruses is mainly due to the expression of TLR7 and 9 in the endosomes, which 
interact with ssRNA and unmethylated CpG motifs respectively [60]. Moreover, a unique pathway 
involving a constitutive expression of IRF7 is responsible for the rapid transcription and of type I 
IFNs. This pathway allows pDCs to respond efficiently and very rapidly to viruses, a mechanism 
which is in contrast to type I IFN induction in cDCs and MΦ where upon TLR3 activation leading to 
IRF3 translocation, only limited quantities of type I IFN are secreted. Another striking difference 
compared to the biological activity of cDC is the low phagocytosis levels and antigen presentation 
capacity of pDCs making them less efficient to activate T cell proliferation. Several routes of entry can 
be used by viruses including phagocytosis, macropinocytosis caveolae- or clathrin-dependent 
endocytosis [23, 61]. During the maturation of endosomes, low pH is required to expose nucleic acid 
to the compartments that express TLR7/9. Inhibitors of endosomal acidification such as chloroquine of 
bafilomycine have been found to abolish the immunostimulatory properties of CpG [62]. Investigation 
on pDC ontogeny showed that this subset arise from the hematopoietic lineage. The development of 
pDCs is mainly driven by the cytokine Fms-related tyrosine kinase 3 ligand (Flt3-L) [63]. 
Furthermore, due to a high expression of IL-3R, the survival of pDCs can be increased by IL-3 
treatment [64]. Throughout life, pDCs originate from hematopoietic cells and migrate from the blood 
to lymphoid organs fulfilling their role of sentinels [61]. 
Porcine pDCs were identified as a population of non-adherent, non-T, non-B, CD4+ and MHCII+ cells 
and by their ability to respond to transmissible gastroenteritis virus (TGEV) secreting massive 
amounts of IFN-α [65]. Further investigations by immunohistochemistry in organs from TGEV-
infected pig revealed the presence of pDCs in lymphoid tissues indicating that these cells are able to 
migrate in lymph nodes [66, 67]. Few years later, this subset was phenotypically characterized as 
CD172alowCD4highCD14-CD163- in peripheral blood mononuclear cells (PBMCs) with a frequency of 
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0.1-0.5% [68]. In addition to TGEV and type-A CpG [69], numerous porcine viruses including 
influenza virus [70], foot and mouth disease virus (FMDV) [71, 72] and classical swine fever virus 
(CSFV) [73] can be sensed and differentially promote IFN-α induction in pDCs in vitro.  This function 
of viral sensing is in part influenced by the cytokine microenvironment. It has been noticed that type I 
and II IFNs, Flt3-L and IL-4 enhance the IFN-α levels produced by pDCs after CpG and FMDV, while 
IL-10 reduces this response [74]. 
 
4.2. Brief history of porcine circovirus-associated diseases 
In 1991, a first outbreak of porcine wasting disease was observed in Canada and multiple tests of 
diagnosis failed to enable the identification of known pathogens. In 1996, Harding and Clark described 
an emerging disease characterized by wasting and dyspnea referred to postweaning multisystemic 
wasting syndrome (PMWS) [75]. Porcine circovirus type 2 (PCV2) was isolated from pigs with 
PMWS in 1998 [76, 77] and referred as Stoon 1010 isolate (isolate of Saskatoon). Interestingly, a 
different type of non-pathogenic circovirus, namely the porcine circovirus type 1 (PCV1), was 
previously reported to infect the PK-15 cell line [78], which prompted the identification of PCV2 as 
one of the causes in the development of PMWS [79]. The two circoviruses were genetically related but 
less than 80% nucleotide sequence identity were found between several type 2 and the non-pathogenic 
type 1 of circovirus [80]. Reproduction of PMWS was achieved in gnotobiotic pigs inoculated with 
homogenous material from PMWS-suffering animals. Nevertheless, porcine parvovirus (PPV) was 
also reisolated during this study [81]. It was postulated that PCV2 was required for the development of 
PMWS, however, other unidentified factors such PPV were also thought to contribute to the 
development of characteristic lesions and other clinical symptoms. Few years later, a report by 
Krakowka and colleagues demonstrated that PMWS can be caused by the inoculation of PCV2 
implemented by non-infectious stimulation of the host immune system [82]. Reflecting the fact that 
many infected animals are asymptomatic, it is now accepted that PCV2 itself is not sufficient to induce 
the disease, but that concurrent pathogens or cofactors lead to the appearance of PMWS [83]. 
Currently, PMWS has been enclosed with many other syndromes disease termed as porcine circovirus 
diseases (PCVD) in Europe [84] or porcine circovirus-associated disease (PCVAD) in North America 
[85] and PCV2 is ubiquitously distributed in the pig population worldwide. How PCV2 evolved and 
its origin are not well defined but few evidences by comparing the nucleotide sequences of several 
ssDNA viruses indicate some similarities with plant nanoviruses and geminiviruses [86]. It was 
hypothesized that PCV2 was transfer to vertebrates from plant infected sap [87]. The scientific 
community agreed on a nomenclature defining three genotypes of PCV2, termed as PCV2a (Stoon 
1010, GenBank accession number AF055392), PCV2b (48285, accession number AF055394) and 
PCV2c (GenBank accession number EU148503) [88]. It has been proposed that circovirus isolates 
related to PCV2b genotype were more associated to PCVD outbreaks than PCV2a genotype, albeit it 
has not been confirmed yet [89]. In Switzerland, both PCV2a and PCV2b have been isolated in swine 
populations [90]. Since the past 10 years, several vaccines have been developed and are available on 
the market for the pig industry. Although they confer protection and reduce the impact of PCVD in 
swine industry [91], the virus is now circulating in the vaccinated pig population. 
 
4.2.1. Impact and clinical signs of PCVD 
PCVD encompasses a variety of syndromes, which include PMWS, the most characterized of 
circovirus-associated diseases. Actually, it is assumed that most of PCV2 infections lead to subclinical 
manifestation only. Nonetheless, with a worldwide distribution, PCVD morbidity and mortality varies 
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between 4 to 30% and 4 to 20% depending on the farms, respectively. A new nomenclature has been 
proposed to term the syndromes based on accurate and defined symptoms observed in PCVD-suffering 
pig [92]. PMWS is considered as a multifactorial disease where infections of PCV2 is necessary, but 
experimental infection hardly reproduces the disease described in the fields [93-95]. The main clinical 
features of pigs suffering from PMWS include wasting, growth retardation, dyspnea and enlargement 
of subcutaneous lymph nodes. Reports from PMWS-affected farms also described that other 
symptoms such jaundice, pallor of the skin, diarrhea can be associated [75, 96]. Further investigations 
using in situ hybridization and immunohistochemistry in PWMS-affected pig revealed macro- and 
microscopic lesions characterized by a loss of architecture in lymph nodes, lymphoid depletion and 
histiocytic infiltrations. Furthermore, PCV2 nucleic acids and antigens are strongly associated with 
lymphoid organs [97, 98]. Since the symptoms characterizing PMWS are not specific for PCV2 
infections, the presence of PCV2 antigens and DNA as well as the typical lesions in lymphoid organs 
are required for an appropriate diagnosis of the disease. These findings indicate that PCV2 has a 
tropism for the cells of the lymphoid system and accordingly, it has been proposed that the virus 
causes immunosuppression by a not well understood mechanism [91, 99-101]. Many research groups 
attempted to reproduce with moderate success the clinical form of PMWS using several model of 
coinfections with bacterial pathogens [102-104] or viruses [81, 94, 105, 106]. Even though many 
extensive efforts have been carried out to explain the immunological basis of PCV2, it is not clearly 
understood why certain animals will development PCVD and others not. Since the past few years, 
successful vaccinations have drastically reduced the impact of PCVD and little attention is currently 
paid to the immunobiology of PCV2. 
 
4.2.2. Biology of PCV2 
Genome organization: 
PCV2 belongs to the Circoviridae family. The non-encapsulated ssDNA genome of the prototype 
PCV2 Stoon strain is 1768 nucleotides long [80]. Therein, circoviruses represent one of the smallest 
viral genomes autonomously replicating in mammalian cells. The icosahedral virions form a 17-25 nm 
diameter size particle. PCV2 genome is composed of 3 major open reading frames (ORFs) which 
encode for 4 proteins, although 6 additional viral transcripts (including 3 rep-associated RNAs: Rep3a, 
Rep3b and Rep3c and 3 minor NS-associated RNAs: NS515, NS672 and NS0) have been detected from 
PCV2-infected cells [107]. The ORF1 is located on the genomic strand leading to the expression of 2 
viral RNA spliced transcripts, termed as rep and rep’ which are translated into Rep and Rep’ proteins, 
both involved in viral replication [108]. ORF2 and ORF3 are found on the complementary strand of 
PCV2 genome. ORF2 encodes the capsid protein (Cap), which represents the only structural protein. It 
has been shown that recombinant Cap self-assembles to form virus-like particles of similar size as 
PCV2 virion [109], which can be employed as vaccines [110]. ORF3 encodes a small protein, which is 
involved in virus-induced apoptosis in PK-15A cell line [111]. The role of the 6 viral RNA transcripts 
is not known and their expression into protein has never been shown suggesting that they may 
contribute to facilitate PCV2 replication [112]. The origin (ori) of viral replication has been mapped 
for PCV1 genome only [113]. The intergenic region between the 5’-ends of rep an cap contains a 
potential stem-loop structure shared by other nanoviruses and geminiviruses [86], which is one of the 
feature of viruses replicating through rolling-circle replication (RCR) [114]. 
Target cells: 
In vivo, PCV2 DNA and antigens have been associated with numerous cell types of the monocytic 
lineage using in situ hybridization and immunohistochemical approaches [97, 98, 115]. Due to the 
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observed depletion of lymphocytes in PCVD-affected pigs, the ability to PCV2 to replicate in these 
cells has been examined and the data are controversial. In the study of Gilpin and colleagues, PCV2 
did not infect resting lymphocytes in vitro according to flow cytometry analysis [116]. Conversely, Yu 
et al. detected cap mRNA and PCV2 DNA in both T and B lymphocytes either from PBMC or 
bronchial lymph nodes from PCV2-infected animals [117]. In another study, PCV2 antigens have been 
observed in certain subpopulations of CD4+, CD8+ and IgM+ cells [118]. These cells were extracted 
from the inguinal lymph node of infected pigs treated with Concanavalin A (ConA), which induces 
lymphocyte proliferation. More recently, increasing copy number of PCV2 genome has been shown in 
cocultures of PCV2-free monocyte-derived dendritic cells (MoDC) and ConA-stimulated PCV2-
inoculated lymphocytes. In contrast, no increase in PCV2 copy numbers was found in PCV2-
inoculated MoDC and ConA-stimulated lymphocytes cocultures [119]. Although these data confirmed 
that PCV2 can replicate in vitro in mitogen-activated lymphocytes, it cannot be confirmed that 
lymphocytes represent the main target cells for PCV2 replication. Interestingly, PCV2 quantification 
has also been performed in fetuses after intra-foetal inoculation of sows resulting in a high viral titer 
and significant high number of PCV2 positive cells in the heart and liver of infected fetuses [120]. 
Furthermore, MΦ, cardiomyocytes and hepatocytes were also infected in foetal stages whereas only 
MΦ were susceptible after post-natal infection suggesting that PCV2 changes its tropism during pig 
development [121]. From in vitro studies, it has been shown that multiple cell types can be infected by 
PCV2. Infection was observed in PK-15 cell line [77], porcine alveolar macrophages (PAM), fetal 
cardiomyocytes [122], porcine monocytic 3D4/31 cell line [123], endothelial PEDSV.15 cell line, 
primary porcine aortic endothelial cells, gut epithelial cells, MoDC and fibrocytes [124]. In summary, 
PCV2 is strongly associated with lymphoid tissues and monocytic cells but is not restricted to these 
subsets. The primary in vivo target cell type for PCV2 replication has not been identified yet. 
Replication: 
PCV2 was found to bind to heparan sulfate and chondroitin sulfate B glycosaminoglycans (GAGs) and 
was internalized slowly in a clathrin-dependent process in the porcine monocytic 3D4/31 cell line 
[123, 125]. Following internalization, PCV2 may escape the endosome during pH acidification process 
since chloroquine inhibits PCV2 internalization [123]. However, PCV2 internalization seems to occur 
in a different way in the PK-15 epithelial cell line because inhibition of pH acidification enhances 
PCV2 replication [126]. Once PCV2 capsid is disassembled by host proteases, PCV2 DNA must enter 
the nucleus to have access to host replication machinery [127]. The stem-loop structure located in the 
ori and the amino acid sequence in Rep protein form motifs which suggest that circoviruses replicate 
through RCR [114]. This mechanism of replication have been described for other phylogenetically 
related viruses such as geminiviruses [128] and nanoviruses [129]. Basically, RCR includes 4 steps: 
conversion of ss- to dsDNA replicative forms, initiation of replication, elongation and termination 
[112]. The first step of replication consists in synthesizing the complementary strand by the host 
enzymes. Accordingly, it was suggested that PCV2 could only replicate in dividing cells, which are in 
the S phase of the cellular cycle. This idea is supported by the fact that only ConA-stimulated 
lymphocytes could support PCV2 replication [118, 119] and not resting lymphocytes [116]. The 
replication of PCV2 requires the formation Rep-Rep’ complex to synthesize viral DNA. Progeny of 
virus can be observed after 20 h post-infection [130] but this does not cause typical cytopathogenic 
effect (CPE) in PK-15A. The mechanism of export used by PCV2 to reach the extracellular space has 
not been investigated yet. Interestingly, both IFN-α and IFN-γ can enhance yield of PCV2 progeny in 
PK-15A [131, 132]. This observation can be attributed to the presence of an ISRE-like sequence in the 
PCV2 genome [133]. 
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4.2.3. Type I IFN response to PCV2 
The fact that PCVD is often associated with other viral or bacterial pathogen infections, or that an 
activation of the immune system is required to trigger the disease suggested that PCV2 could modulate 
the host immune response [91, 99-101]. Although PCV2 is associated with cells of the monocytic 
lineage, the virus does not efficiently replicate in these cells but rather accumulates insight [116]. 
Moreover, PCV2 amasses in MoDC or BMDC without showing any signs of replication or disturbing 
the capacity of these cells to present antigens [134, 135]. An early report showed that PCV2 alone can 
induce IFN-α in PAM in vitro [136]. In contrast, it has been shown that PCV2 did not induce IFN-α or 
even impaired CpG-induced IFN-α response in CD172a-enriched cells [135]. A closer examination of 
the interactions between PCV2 and pDCs revealed that the inhibition is mediated by PCV2 DNA. 
Moreover, the IFN-α inhibition is also affected when other ligand such as TGEV or the TLR7 agonist 
R837 are employed [137]. Further analysis of PCV2 DNA content in viral preparations showed that 
only free dsDNA forms of PCV2 have the capacity to interfere with IFN-α secretion [138]. This 
observation could reflect the fact that large quantities of PCV2 DNA replicative forms are found in 
lymphoid tissues of PMWS-suffering pigs [139], thus modulating the immune response in these 
animals. Other reports demonstrated that five CpG motifs derived from PCV2 genome have different 
stimulatory properties in PBMCs. Four of these sequences are stimulatory, whereas the remaining 
CpG motif inhibits in vitro secretion of IFN-α in PBMCs [140]. The IFN-α inhibition mediated by this 
CpG motif is dependent on the hairpin structure formed by the sequence [141], while the methylation 
status does not alter its inhibitory property [142]. Nonetheless, IFN-α has been detected in the serum 
of PCV2-infected pigs [143, 144], indicating that the interaction of PCV2 and pDCs might be much 
more complex. However, the relevance of such a response is not known in in vivo context yet. A type I 
IFN response can be thought to favor PCV2 replication [133] increasing the chance for disease 
development. 
 
4.3. Brief history of porcine reproductive and respiratory syndrome 
The first cases of porcine reproductive and respiratory syndrome (PRRS) appeared in the United States 
of America and in Europe in latest 1980s. Even though several clinical manifestations have been 
observed, characteristic syndromes are reproductive failures and respiratory distress [145, 146]. 
Porcine reproductive and respiratory syndrome virus (PRRSV) was then recognized as the causative 
agent of PRRS in Europe [147] and the United States [148, 149] and was referred as Lelystad virus 
(LV) and VR-2332, respectively. While both isolates emerged simultaneously in Europe and in the US 
inducing similar clinical signs, it appeared that only 55-79% identity in amino acid sequences were 
shared by these two viruses [150]. Since the early 1990s, PRRSV has started to spread across Europe 
and North America especially in pig-growing areas. It becomes clear that two distinct genotypes of 
PRRSV evolved divergently which were assigned as to either genotype 1 (European; PRRSV-1) 
represented by the prototype LV, or to genotype 2 (North American; PRRSV-2) with VR-2332 as 
reference strain. Moreover, sequence analysis of PRRSV isolates showed a considerable genetic 
variation within a genotype, which can be cluster into several subtypes of PRRSV [151, 152]. So far, 
phylogenetic analysis of ORF5 and ORF7 from genotype 1 classified the European PRRSV into 4 
subtypes including Western European subtype I, II and III and Russian subtype I. Moreover, a larger 
heterogeneity has been described for PRRSV-2, which comprise at least 9 lineages [153]. Currently, 
PRRSV is spreading throughout the world and episodically give rise to the emergence of highly 
virulent isolates related to PRRSV-2 in North America but also in Asia since 1997 [154, 155]. The 
origin of PRRSV is still unknown although the PRRSV seems to be related to the lactate 
     
 
 
 
14 
 
dehydrogenase-elevating virus (LDV) suggesting that both PRRSV genotypes diverged from a 
common precursor and that the speciation of the two current known genotypes arose latter than LDV 
variants [150]. Due to contaminations of semen used for inseminations, some sows in the Eastern 
region of Switzerland were found to be PRRSV positive by qPCR in December 2012. The infected 
herds were slaughtered to avoid any outbreaks and virus spreading. Thus, the worst scenario was 
avoided because the immune status is naïve in pigs growing in Swiss area. Due to the large 
heterogeneity of the virus and its weak immunogenicity, the development of successful vaccines is 
currently of major importance and many efforts are consumed to improve the knowledge of 
immunological basis of PRRSV which will help for vaccine design. 
 
4.3.1. Impact and clinical signs of PRRS 
PRRS appears as one of the most important emerging disease affecting the swine industry. For 
instance, the cost associated to PRRS is estimated at up to 560 million US dollars per year in the USA 
[156]. The outcome of PRRS results of complex interactions between the virus and host factors 
including the age, the presence of other bacterial or viral pathogens as well as the pregnant status of 
sows, in which the infection can lead to late-term abortion and stillborn mummified fetuses. The 
symptoms in sows greatly vary from none to fever, lethargy, pneumonia and blue coloration of the 
ears. Infections of neonatal pigs demonstrate more profound respiratory distress and higher 
susceptibility to bacterial or viral co-infections where mortality can reach 100% in certain herds [157]. 
According to several reports, it is well accepted that PRRSV-2 causes more profound pathological 
lesions [158-160]. However, it seems that emergence of new isolate belonging to genotype 1 can 
provoke severe clinical signs [161]. Additionally, evidence from published observations showed that 
PRRSV can persist in infected animals and can be detected at 105 days post infection [162]. Although 
the lung tissues, especially PAM are the main sites of PRRSV replication [163], Rowland and 
colleagues were able to recover the virus from lymphoid organs or tonsils at 132 days after birth in 
congenital infected pigs [164]. These data suggest that PRRSV can persist for long period and may 
escape the immune responses. Indeed, PRRSV infection is characterized by a delayed appearance of 
neutralizing antibodies and a poor cell-mediated immunity [165]. Accordingly, PRRSV increases the 
susceptibility of pigs to secondary bacterial and viral infections in the respiratory tract [166]. The 
mechanisms by which PRRSV evades the host immune system have unfortunately not yet been 
elucidated. Moreover, due to large heterogeneity amongst PRRSV isolates and limited understanding 
of PRRSV immunobiology, vaccine development remains one of the biggest challenge in the future 
research [167]. 
 
4.3.2. Biology of PRRSV 
Genome organization: 
PRRSV is an enveloped positive ssRNA virus and belongs to the Arteviridae family which also 
include LDV, equine arteritis virus (EAV) and simian hemorrhagic fever virus (SHFV) [168]. The 
viral genome of approximately 15kb encodes for 7 subgenomic mRNA transcripts, each of them 
containing one or two ORFs for protein translation [169]. The non-structural pp1a and the larger 
pp1ab polyproteins are translated from full-length viral RNA. The pp1ab is expressed from a 
ribosomal frame shift. These two polyproteins are then cleaved by viral proteases to give rise to 14 
non-structural proteins [168, 170] including proteases (NSP1α, NSP1β, NSP2 and NSP4), an RNA-
dependent RNA polymerase (NSP9), a helicase (NSP10) and an endoribonuclease (NSP11) [171]. 
Whilst some of the non-structural proteins of PRRSV have still unidentified structure and unknown 
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function, NSP2 seems to be of particular interest since the amino acid sequence represent only 32% 
identity between PRRSV genotypes [172]. The structural proteins are translated from ORFs 2-7. The 
ORFs 2-5 encode for the glycosylated envelope proteins GP2, GP3, GP4 and GP5. The non-
glycosylated M and the nucleocapsid (N) proteins are expressed through ORF6 and ORF7 respectively 
[173]. The small E protein is translated from ORF2b, which is included in the ORF2 [174]. 
Target cells: 
PRRSV has shown to have a restricted tropism for the MΦ/monocytic lineage. Antigens of PRRSV 
have been observed in alveolar MΦ in the lungs and in other lymphoid tissues [163, 175]. Replication 
of PRRSV in vitro has been detected in PAM [176], MoDC [177-180], bone marrow-derived dendritic 
cell (BMDC) [181], monocyte-derived macrophages (MDM) [182] and MARC-145 [183]. Whilst 
PRRSV can infect MoDC and produce virus progeny, it is not clear if replication may occur in 
primary DC in vivo. In the study of Loving and colleagues, virus quantification using an end-point 
titration and qPCR in the supernatants of lung DC did not show an increase of PRRSV titers or viral 
copy number respectively [184]. Using a GFP-tagged PRRSV it was observed that pDCs are refractory 
and do not support virus replication [185]. Additionally, PRRSV does not replicate in vitro in primary 
monocytes [176]. In summary, it can be concluded that cells susceptible to PRRSV are closely 
associated to the MΦ lineage and less to the DC subsets. However, since MΦ comprise a 
heterogeneous cell population [186], future studies might be devoted to assess if some of the MΦ 
subsets are differentially susceptible to PRRSV. 
The MΦ originates from blood monocytes following cellular differentiation in specific tissues. Since 
PRRSV specifically targets the MΦ lineage in the lung, the understanding of MΦ biology is highly 
relevant. The renewing of lung MΦ mainly comes from blood precursors but also from local 
progenitor cells. Based on the anatomical location, the lung MΦ comprise three major subsets 
including PAM, interstitial and intravascular MΦ which differentially express TLRs [187]. The 
differentiation of MΦ is driven by the cytokine microenvironment, which plays a critical role in the 
activation of different functional MΦ. This functional classification is based on MΦ polarization into 
classically (M1) or alternatively (M2) activated MΦ. While M1 MΦ polarization is stimulated by IFN-
γ, the M2 MΦ mainly require the presence IL-4 or IL-13. The M1 activation promotes inflammatory 
responses and increases the microbicidal activities of MΦ to destroy and eliminate intracellular 
pathogens [14]. Important sources of IFN-γ which results into M1 polarization include the NK and Th1 
cells [188]. Alternatively, M2-driven responses by MΦ lead to anti-inflammatory cytokine secretions 
and tissue healing. The cytokines which activate such MΦ are secreted by polymorphonuclear cells 
(PMNC) as well as the CD4+ lymphocytes from Th2-like responses [189]. Thus, M2 MΦ can be 
considered as “regulatory” MΦ by their ability to secrete IL-10 and other mediators involving in the 
processes of wound healing and fibrosis. Nonetheless, little information is available on the phenotype 
and functionality of M1- or M2-activated MΦ in the pig model. It is not known if cytokine-mediated 
polarization of MΦ could influence the susceptibility of these cells to PRRSV. 
Replication: 
The scavenger receptor CD163 is employed by PRRSV for binding and penetration into the cells. This 
receptor was isolated from screening of a PAM cDNA library. The transfection of cDNA encoding 
CD163 showed that it was sufficient to render non-permissive cells susceptible to PRRSV infection 
and replication [190]. Following entry and uncoating of PRRSV, the translation of nonstructural 
proteins starts at ORF1a and employs full-length genomic RNA. The ORF1a is connected to ORF1b 
by a ribosomal frame shift, which leads two polyproteins pp1a and pp1ab. Post-translationally 
processing by viral autoproteinases encoded by pp1a is required to release the nonstructural proteins 
     
 
 
 
16 
 
and assemble into a membrane-associated viral replication and transcription complex (RTC). The 
NSP9 RNA-dependent RNA polymerase recognizes a signal sequence in the 3’-end of genome and 
initiates the synthesis of the genomic negative-stranded RNA as well as subgenomic RNAs [191]. It is 
thought that these minus-strands serve as template for the transcription of positive subgenomic 
mRNAs and facilitate PRRSV replication. The structural protein are then translated from subgenomic 
mRNAs by host ribosomes [192]. Following the encapsulation of the genome by the N protein, new 
virions are formed by budding from the membrane of the endoplasmic reticulum to the Golgi pathway. 
The replication cycle of PRRSV takes around 12 h in PAM and is followed by CPE and cell lysis. 
 
4.3.3. Type I IFN responses to PRRSV 
One important feature of PRRSV infection is the ability of the virus to induce any or only limited 
quantities of type I IFN and other proinflammatory cytokines in the lung tissues [193, 194]. Since the 
lack of type I IFN could play a role in PRRSV pathogenesis and explain the weak adaptive immune 
response and persistence of the virus [165], many studies have been performed to understand how 
PRRSV manipulate host immunity. Quantifications of PRRSV-induced IFN-α in vitro revealed that 
this cytokine is not secreted by PAM [193] and MoDC [195, 196]. In the study of Lee and colleagues, 
it was reported that the ability of the virus to induce IFN-α in PAM depends on the PRRSV isolates 
and even isolate-derived plaque clones [197]. These data suggest that PRRSV can strongly differ in its 
ability to influence type IFN secretion, which may relate to virus isolates or even to quasispecies. 
Importantly, PRRSV is highly sensitive to the presence of type I and III IFN in vitro [184, 198, 199] 
and to type I IFN in vivo [200]. 
Many research groups have focused on the mechanism used by PRRSV to inhibit type I IFN secretion 
in cells susceptible to infection such as MARC-145. No significant upregulation of IFN-α2 and IFN-β1 
transcripts has been noted in PRRSV-infected MARC-145 [201]. Further investigations using IFN-β 
promoter luciferase reporter system suggested that PRRSV has the ability to inhibit IRF3 activation 
but not NF-κB and AP-1. The authors propose that the inhibition of IFN-β is attributed to the 
interaction of PRRSV with IPS-1, the downstream element of RIG-I signaling cascade [202]. Work by 
others showed that four of PRRSV nonstructural proteins including NSP1, NSP2, NSP4 and NSP11 
inhibit IRF3- and NF-κB-dependent gene expression upon dsRNA stimulation in TLR3-expressing 
HEK293T cells [195]. In another study, it was also noticed that NSP1 reduced phosphorylation of 
IRF3 which in turns limits the induction of IFN-β in MARC-145 [203]. In addition to its ability to 
suppress type I IFN induction, PRRSV NSP1β can alter the signaling pathway by inhibiting STAT1 
phosphorylation [204]. On the other hand, PRRSV is found to prevent the translocation of ISG3F into 
the nucleus [205]. However, this model based on MARC-145 does not seem to fully reflect the 
susceptible host cells, since Gemini and colleague observed an upregulation of IFN-β transcripts in 
PAM [206]. Similarly, IFN-α/β transcripts have been detected in MoDCs [196]. PRRSV must rather 
inhibits the type I IFN induction through its rapid cytopathogenicity in host cells because UV-
inactivated viruses loses the capacity to interfere with type I IFN production by TGEV or poly(I:C) 
[207]. Recent reports showed that pDCs did not respond to North American PRRSV [208] and that 
CpG-induced IFN-α was inhibited in these cells [185]. However, accumulating evidence from 
published reports suggest that certain cell types are able to sense PRRSV infection since significant 
levels of IFN-α has been detected in the serum of infected pigs [193, 209, 210]. The report from 
Barranco et al. even demonstrated the presence of IFN-α secreting cells in lymphoid organs after 
PRRSV-1 challenge [211]. Despite many reports suggesting the suppressive activity of PRRSV 
regarding the type I IFN system [212, 213], this alone may not explain the delayed adaptive immune 
response. It seems that many additional factors may contribute to the uncommon immune response 
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against PRRSV. These include a particular cytokine microenvironment, downregulation of molecules 
related to antigen presentation and the presence of a decoy epitope in GP5 distracting the adaptive 
immune response for the production of neutralizing antibodies [214]. 
 
4.4. Cathelicidins and the type I IFN system 
Host defense peptides (HDP), also termed as antimicrobial peptides encompass a variety of small 
proteins, which are involved in the innate defense mechanisms. HDPs comprise two main families 
including the defensins and cathelicidins. Defensins are short peptides characterized by 6 cysteins with 
various disulfide bound configurations and have strong antimicrobial properties as well 
immunomodulatory functions [215]. Regarding the cathelicidins, they represent a more heterogeneous 
group of peptides. All of them possess an N-terminal signal sequence, a cathelin-like domain and 
various antimicrobial regions in the C-terminal part [216]. The great diversity of the C-terminal 
enables to categorize the cathelicidins in 3 classes which include the proline- and arginine-rich, 
cysteine-rich and the α-helical peptides [217]. These peptides are temporally stored as propeptide 
form within neutrophil granules. The C-terminal domain of the molecule requires activation by 
elastases which cleave off the propeptide form to release the bioactive cathelicidin [218-220]. 
Additionally, the expression of cathelicidins is inducible in keratinocytes and has been detected in NK 
cells, B cells, monocytes/MΦ and bone marrow cells [221-223]. Interestingly, only one member 
referred as LL-37 has been found in humans, whereas 11 cathelicidins have been isolated in swine. 
The porcine cathelicidin family comprises the prophenin-1 and -2, proline-arginine-rich 39-amino-acid 
peptide (PR-39), disulfide-bridged cystein-rich protegrins (PG-1 to PG-5) and α-helical porcine 
myeloid antimicrobial peptides (PMAP-23, PMAP-36 and PMAP-37). Remarkably, all cathelicidins 
harbour a high cationic charge for a size of 12–100 amino-acid residues [224]. The immunological 
properties of LL-37 have been the most studied so far. This peptide belongs to the α-helical peptides 
and has typical amphipathic configuration. It has been demonstrated that LL-37 displays a wide 
antimicrobial activity against several Gram- and Gram+ bacteria as well as immunomodulatory 
functions [225]. For instance, recent reports demonstrated that human LL-37 is able to promote rapid 
sensing of CpG motif-containing oligodeoxyribonucleotides (CpG-ODN) by pDCs [226]. The 
complexing of self DNA by LL-37 resulting in pDC activation has been proposed to play a role in the 
pathogenesis of some autoimmune diseases [227, 228]. Although the antimicrobial activity of porcine 
cathelicidins is well documented, little is known about their immunomodulatory function and their 
interaction with pDCs. 
 
4.4.1. Antimicrobial activity 
The interface between cathelicidin and the target organisms has been quite well characterized for the 
human LL-37. Early publication already demonstrated that LL-37 is a potent antimicrobial agent [229, 
230]. Bacterial killing is mediated by disrupting bacterial membrane integrity [231]. The cationic 
moieties of LL-37 enable an interaction with negatively charge residues on bacterial surface. 
Subsequently, the peptide accumulates in carpet like-structure due to the parallel orientation of the 
amphipathic helix on the bacterial surface. This mechanism induces leakage probably by bytoroidal 
peptide-lipid pore formation until the membrane completely collapses [217, 232]. In contrast, the 
biochemical properties of PR-39 suggest that the microbicidal activity is not mediated by lytic 
mechanism but rather by targeting cellular components [224]. The peptides PR-39 [233, 234], PMAP-
23 [235, 236], PMAP-36 [237, 238], PMAP-37 [239] have been reported to kill many pathogens 
including Gram+ and Gram- bacteria. The PGs as well as the two prophenins have also been found to 
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mediate antimicrobial activity summarized in a review [224]. Depending on the pathogens, the 
minimal inhibitory concentration ranges from 0.5 to 50 µM but can be higher for resistant pathogens 
such as Pseudomonas aeruginosa or Staphylococcus aureus [224]. Importantly, cholesterol prevents 
membrane damage. This explains why physiological concentrations of cathelicidins do not injury host 
cells which contain cholesterol in their membrane [240]. 
 
4.4.2. Immunomodulatory functions 
The human LL-37 have been reported to have multiple effects on the immune system. First, it has been 
shown that this cationic peptide can neutralize LPS toxin reducing the danger of septic shock [241]. In 
addition, it exhibits cell chemotaxis [222] and participates to MΦ differentiation [242] and activation 
[243, 244]. Investigations on MoDC differentiation indicated that the presence of LL-37 influences the 
expression of several cell surface markers relevant for the antigen presentation process. Moreover, LL-
37-treated MoDC have higher phagocytic activity and stronger potential for inducing Th1 cell 
polarization compared to control MoDC [245]. Due to the implication of LL-37 in antigen presentation 
as well as in the process of inflammation, it can be proposed that this peptide links both innate and 
adaptive immunity. Following infection, tissue damage needs to be repaired. The binding polyvalence 
of LL-37 to multiple receptors involving the processes of wound repair and angiogenesis also suggest 
implication of this peptide in tissue healing [246]. Finally, another report showed that copious amounts 
of IFN-α can be induced by pDCs due to the rapid delivery of CpG-ODN complexed to LL-37 [226]. 
This mechanism has been proposed to be involved in the pathogenesis of psoriasis and Lupus 
Erythematosus autoimmune diseases where high levels of LL-37 have been detected in the lesions of  
patients [227, 228]. 
Regarding the porcine cathelicidin only PR-39 has been described to have other functions than 
antimicrobial effects. This includes the chemotaxis of neutrophils [247] and angiogenesis [248]. 
Interestingly, PR-39 has potent capacity to deliver small interfering RNA into the cells [249]. Apart 
from the antimicrobial activity, nothing is currently described on the influence that PMAPs could have 
in the modulation of some immune cells.  
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5. Goals 
Due to the important and crucial role of type I IFNs during an immune response, the first objectives 
were to evaluate and clarify the interaction of two known immunosuppressive viruses, PCV2 and 
PRRSV, with pDCs. Previous report demonstrated that PCV2 inhibits IFN-α production in pDCs in 
vitro in response to TLR7 or 9 agonists [137]. This inhibition of IFN-α has been attributed to the 
presence of the dsDNA replicative form of PCV2. Conversely, IFN-α was not inhibited in pDCs in 
some PCV2 preparations [138]. Furthermore, detectable levels of systemic IFN-α were found in the 
serum of PCV2-infected pigs [143, 144], thereby questioning the function of PCV2 in modulating 
IFN-α in pDC responses. In parallel, a recent study on North American PRRSV genotype 2 isolates 
showed that the virus did not induce, or even strongly inhibited IFN-α in pDCs [185]. However, again 
many studies demonstrated that significant IFN-α amounts were quantified in pigs which were 
infected with various PRRSV strains [193, 209, 210]. Thus, the aims of the first part of my Thesis 
were to clarify host and viral factors, which could potentially influence the function of pDCs and type 
I IFN induction by PCV2 and PRRSV. 
PRRSV has natural tropism for cells of monocytic lineage with a particular affinity for alveolar MΦ in 
the lung tissues and lymphoid organs. Therein, the understanding of MΦ biology is primordial to study 
PRRSV within its natural host. In the second part of this Thesis we therefore focused on the influence 
of IFN-γ (M1), IL-4 (M2) and IFN-β activation of MΦ on the susceptibility to genotype 1 and 2 
PRRSV strains varying in virulence. 
The third part of my Thesis is based on a recent report demonstrating that the human LL-37 promotes 
rapid sensing of CpG-ODN inducing large amounts of IFN-α by pDCs [226]. Except to their broad 
antimicrobial activity, nothing is known about the participation of porcine cathelicidins in pDC-driven 
innate immune responses.  We considered that such functions are relevant to both PRRSV- and PCV2-
mediated diseases, which are very often associated with bacterial co-infections. Consequently, we 
evaluated the ability of three selected porcine cathelicidins, PR-39, PMAP-23 and PMAP-36, to 
interact with different types of nucleic acids and mediate pDC activation.  
     
 
 
 
20 
 
6. Results 
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Porcine circovirus type 2 stimulates plasmacytoid dendritic cells in the presence of IFN-gamma 
 
 
Published in Veterinary Immunology and Immunopathology. 
     
 
 
 
21 
 
 
     
 
 
 
22 
 
 
     
 
 
 
23 
 
 
     
 
 
 
24 
 
 
     
 
 
 
25 
 
  
     
 
 
 
26 
 
  
     
 
 
 
27 
 
6.2. Manuscript 2 
Impact of genotype 1 and 2 of porcine respiratory syndrome viruses on interferon-α responses by 
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Virulence and genotype-associated infectivity of interferon-treated macrophages by porcine 
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6.4. Manuscript 4 
Porcine cathelicidins efficiently complex and deliver nucleic acids to plasmacytoid dendritic cells and 
can thereby mediate bacteria-induced interferon-alpha responses. 
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Abstract 15 
Cathelicidins constitute potent antimicrobial peptides characterized by a high cationic charge that 16 
enable strong interactions with nucleic acids. In fact, the only human cathelicidin LL-37 triggers rapid 17 
sensing of nucleic acids by plasmacytoid dendritic cells (pDC). Amongst the porcine cathelicidins, 18 
phylogenetic analysis of the C-terminal mature peptide showed that the porcine myeloid antimicrobial 19 
peptide (PMAP)-36 was the most closely related of the 11 porcine cathelicidins to human LL-37. 20 
Despite several investigations evaluating potent antimicrobial functions of the porcine cathelicidins, 21 
nothing is known about their ability to promote pDC activation. We therefore investigated the capacity 22 
of the proline-arginine-rich 39-amino-acid peptide (PR-39), PMAP-23 and PMAP-36 to complex with 23 
bacterial DNA or synthetic RNA molecules and facilitate pDC activation. We demonstrate that these 24 
peptides mediate a rapid and efficient uptake of nucleic acids within minutes followed by robust IFN-α 25 
responses. PMAP-36 which harbors the highest cationic net charge was found to be the most potent 26 
peptide tested for this effect. The peptide-DNA complexes were internalized and also found to 27 
associate with the cell membranes of pDC. The amphipathic conformation typical of PMAP-36 was 28 
not required for IFN-α induction in pDC. We also demonstrate that this cathelicidin can mediate IFN-α 29 
induction in pDC stimulated by E. coli, which alone fail to activate pDC. This response was weaker 30 
with a non-sense PMAP-36, relating to its lower antimicrobial activity. Collectively, our data suggest 31 
that the antimicrobial and nucleic acid complexing properties of cathelicidins can mediate pDC 32 
activation promoting adaptive immunes responses against microbial infections.  33 
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Introduction 34 
The cathelicidin family together with defensins encompass a wide spectrum of host defense peptides 35 
(HDP) widely referred to as antimicrobial peptides. Cathelicidins are predominantly expressed by 36 
neutrophils in pre-propeptide forms which share an N-terminal signal sequence, a cathelin-like domain 37 
and a highly diverse structural C-terminal part (1). The inactive propeptides are temporally stored 38 
within neutrophil granules, and require activation by elastases which cleave off the C-terminal 39 
bioactive domain of the molecule (2). Interestingly, swine possesses all classes of cathelicidins 40 
observed in higher vertebrates, whereas in humans LL-37 alone has so far been described. The porcine 41 
cathelicidin family includes the prophenin-1 and -2, proline-arginine-rich 39-amino-acid peptide (PR-42 
39), disulfide-bridged cystein-rich protegrins (PG-1 to PG-5) and α-helical porcine myeloid 43 
antimicrobial peptides (PMAP-23, PMAP-36 and PMAP-37) (3). Antimicrobial activity has been well 44 
characterized for PR-39 (4, 5), PMAP-23 (6, 7) and PMAP-36 (8). It was also shown that PR-39 45 
displays chemotatic activity in neutrophils (9). Despite several investigations evaluating the 46 
antimicrobial activity of cathelicidins, nothing is known about their participation in pDC-driven innate 47 
immune responses. 48 
It is widely accepted that type I IFNs, mainly IFN-α/β, are essential to the innate immune system for 49 
direct antiviral defenses as well as robust adaptive immune responses (10, 11). Although plasmacytoid 50 
dendritic cells (pDC) are rare, they act as the ultimate producer of IFN-α, secreting up to 1000-fold 51 
higher levels of type I IFN than any other cellular types (12). They represent the major source of type I 52 
IFNs and other inflammatory cytokines after exposure to TLR7 and TLR9 ligands, including many 53 
viruses and bacterial DNA (13). Consequently, they represent an important target for investigating 54 
early immune events that could influence the induction of adaptive immune responses (14). In pig, 55 
these cells are identified as CD4+CD123+CD135+CD172a+CD14- and can be differentiated from 56 
conventional blood dendritic cells and monocytes that lack CD4 expression (15). 57 
Recent reports demonstrated that human LL-37 was able to promote rapid sensing of unmethylated 58 
CpG motifs inducing large amounts of IFN-α by pDC (16). This mechanism has been proposed for the 59 
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pathogenesis of some autoimmune diseases such as psoriasis and Lupus Erythematosus (17, 18). 60 
Similar to what has been observed with LL-37, human β-defensin 2 and 3 have been shown to enhance 61 
IFN-α response in pDC (19). However, nothing has been described regarding the effect of porcine 62 
cathelicidin in the activation of pDC by microbial nucleic acids. Consequently, the ability of PR-39, 63 
PMAP-23 and PMAP-36 to interact with different types of nucleic acids and their contribution to 64 
activate pDC have been investigated.   65 
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Materials and Methods 66 
Reagents  67 
The PR-39 (RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP), PMAP-23 68 
(RIIDLLWRVRRPQKPKFVTVWVR), PMAP-36 69 
(GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG), a non-sense version (scrambled) of 70 
PMAP-36 (GKIRGKRKKVRPGTIFRLRVLKWIPPIGCKRLSKLG) was generated using solid-phase 71 
peptide synthesis by ChinaPeptides (Shanghai, China). All peptides showed >98% purity by HPLC 72 
analysis and mass spectrometry. Peptides were dissolved in deionized sterile water and stored at -20°C 73 
until further use. Polyuridylic acid (poly(U)) potassium salt and chloroquine diphosphate were 74 
provided by Sigma-Aldrich (Switzerland). Endotoxin-free genomic DNA from E.coli K12 was 75 
purchased from InvivoGen (San Diego, CA, USA). The type-A guanine cytosine 76 
oligodeoxynucleotide (CpG) D32 known to induce IFN-α in porcine pDC (20) was obtained from 77 
Microsynth AG (Switzerland). Another type-A CpG-2216-FITC was purchased from Invivogen and 78 
used for confocal microscopy. Plasmid pEAK8 was propagated in chemocompetent bacteria XL1-Blue 79 
E.coli and transformed bacteria were selected with ampicilin on agar plate. After overnight growth in 80 
lysogeny broth (LB; AppliChem, Switzerland) medium supplemented with ampicilin, plasmid was 81 
extracted from bacteria using the extraction NucleoBond® Xtra Midi kit (Macherey-Nagel GmbH, 82 
Switzerland). The genomic E.coli DNA was labeled with FITC using Label IT® Nucleic Acid 83 
Labeling kit following the manufacture’s instructions (Mirus, Madison, WI, USA). Alternatively, the 84 
Ulysis™ Alexa Fluor® 488 Nucleic Acid Labeling kit was employed for confocal microscopy 85 
following manufacture’s protocol (Life Technologies, Switzerland). The transfection reagent N-[1-86 
(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) was purchased from 87 
Roche (Switzerland) and used following the manufacturer’s instructions. The following mouse mAb 88 
were used: anti-CD172a (mAb 74-22-15a, kindly obtained from Dr. Armin Saalmüller, Veterinary 89 
University of Vienna, Austria), anti-CD4 (mAb PT90A, VMRD Inc., Washington, USA) and anti-90 
IFN-α (mAb F17; R&D Systems). Isotype specific anti-mouse conjugated with FITC, RPE, biotin and 91 
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Streptavidin SpectralRed® (SouthernBiotech, Birmingham, AL, USA), as well as isotype specific 92 
Alexa 546 and Alexa 647 conjugates from Life Technologies (Basel, Switzerland) were employed as 93 
secondary reagents.  94 
Isolation of pDC 95 
Enrichment of pDC was performed as described earlier (20). Briefly, peripheral blood mononuclear 96 
cells (PBMC) from 6 week- to 12 month-old specific pathogen free (SPF) pigs were isolated by Ficoll-97 
Paque differential centrifugation (21) followed by CD172a enrichment using MACS sorting (Miltenyi 98 
Biotec GmbH, Germany). Each enrichment lead to > 80% of CD172a positive cells and 2-5% pDC. 99 
Herein, these CD172a-sorted cells are referred to as “enriched pDC”. To examine the cellular 100 
localization of E.coli DNA in pDC, CD172a-enriched cells were purify by electrostatic sorting based 101 
on a gate on CD172lowCD4high population using a FACSAria Cell Sorter (BD biosciences, 102 
Switzerland). 103 
Stimulation of pDC and quantification of IFN-α by ELISA 104 
Stimulation of pDC was performed in 96-microwell plates at 4x106 cells/ml. The following amounts of 105 
nucleic acid molecules and cathelicidins were employed to form complexes at room temperature (RT) 106 
for 10 min: 1 µg of E.coli DNA (final concentration of 10 µg/ml), 1 µg of pEAK8 plasmid (final 107 
concentration of 10 µg/ml), 0.25 µg of type-A CpG (final concentration of 2.5 µg/ml) or 1 µg of 108 
poly(U) (final concentration of 10 µg/ml) were incubated with 4x10-9 mol and with 4-fold dilutions of 109 
each cathelicidins (final concentration of 40 µM, 10 µM, 2.5 µM and 0.6 µM) in 60µl of DMEM 110 
containing 10% FBS. A volume of 40 µl containing 4x105 enriched pDC were finally added to reach 111 
the concentrations listed above. Cells were incubated for 10 min, washed three times with 200 µl cold 112 
PBS (350g at 4°C for 10 min), and then cultured in 200 µl of fresh DMEM supplemented of 10% FBS 113 
and 20 µM of β-mercaptoethanol (Invitrogen, Switzerland). After 20 h, cultures were centrifuged and 114 
cell-free supernatants were harvested. The levels of secreted IFN-α was quantified in collected 115 
supernatants by ELISA as described in (22). 116 
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Chloroquine (1.25-10 µM) was employed to examine the role of pH endosomal acidification, which is 117 
required for TLR7/9 sensing of nucleic acids (23). A similar protocol was employed except that 118 
enriched pDC were pretreated with increasing amount of chloroquine before being added to E.coli 119 
DNA (10 µg/ml) complexed to PR-39 (40µM), PMAP-23 (40 µM) and PMAP-36 (2.5 µM). Exposure 120 
of the cells to CpG alone was included as control. The cultures were incubated at 39°C for 20 h and 121 
IFN-α was quantified in the culture supernatant by ELISA. 122 
When enriched pDC were stimulated with XL1-blue E.coli, 8x10-9 mol of PMAP-36 or scrambled 123 
peptide followed by 4-fold dilutions (final concentration of 40 µM, 10 µM, 2.5 µM and 0.6 µM) were 124 
incubated with 2x106 bacteria in a volume of 100 µl of FBS free DMEM for 1 h. Finally, 4x105 125 
enriched pDC suspended in 100 µl of supplemented DMEM were added to reach 10% FBS, 20 µM of 126 
β-mercaptoethanol, 1X Pen/Strep (Life Technologies, Switzerland) and the peptide concentrations 127 
mentioned above. Cultures were incubated for 20 h and IFN-α was quantified by ELISA. 128 
Flow cytometry and confocal microscopy 129 
The uptake of E.coli DNA complexed to cathelicidin peptides was performed in 48-well plate. Briefly, 130 
5 µg of FITC-labeled DNA from E.coli K12 (final concentration of 10 µg/ml) was mixed with 131 
1.25x10-9 mol of PMAP-36 (final concentration of 2.5 µM) or 2x10-8 mol of PR-39 or PMAP-23 (final 132 
concentration of 40 µM) in 400 µl of DMEM at RT for 10 min. Then, 100 µl containing 1x106 133 
CD172a+ cells was added to reach the final concentrations mentioned above. The cultures were 134 
incubated at 39°C for 1, 5, 10 or 30 minutes. Cells were then washed with cold PBS and stained with a 135 
monoclonal antibody directed against a CD172a or CD4 epitope in order to identify pDC characterized 136 
as CD172lowCD4high cells. To characterize the intracellular levels of IFN-α, 1x106 CD172a+ cells 137 
were stimulated in a 48-well plate in a final volume 500µl. Similarly to the uptake experiment, 138 
complexes were formed at RT for 10 min before the addition of enriched pDC. Cultures were 139 
incubated at 39°C with either CpG (2.5 µg/ml), E.coli DNA (10 µg/ml) or E.coli DNA + PMAP-36 140 
(10 µg/ml + 2.5 µM) for 10 min. Cells were then washed three times with cold PBS and cultured in 141 
500µl of fresh medium for several time points. Brefeldin A (eBioscience, Austria) was added to the 142 
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cells to block IFN-α secretion for 4 h before stopping the cultures. Culture supernatants were collected 143 
and used to quantify the levels of IFN-α by ELISA. Cells were subsequently stained for surface CD4 144 
and CD172a expression as mentioned above. Cell fixation and permeabilization for intracellular 145 
staining of IFN-α was performed using a Fix & Perm kit (Caltag, UK). Anti-IFN-α, biotinylated goat 146 
anti-mouse IgG1 conjugate and Streptavidin SpectralRed® were added to the cells to detect 147 
intracellular IFN-α. The data were acquired using a FACScalibur (BD Biosciences, Mountain View, 148 
CA) and data analysis was performed using FlowJo software. 149 
For confocal images, pure FACS-sorted pDC were stimulated following a similar protocol used for the 150 
IFN-α quantification. In 96-well plate, 1 µg of E.coli DNA labeled with Alexa 488 (final concentration 151 
of 10 µg/ml) was complexed to 4x10-9 mol of PR-39 or PMAP-23 (final concentration of 40 µM) or 152 
2.5x10-10 mol of PMAP-36 (final concentration of 2.5 µM) in a volume of 75 µl at RT for 10 min. The 153 
control E.coli DNA labeled with Alexa 488 was employed alone. A volume of 25 µl containing 1x105 154 
pure pDC was added in each well and incubated at 39°C for 10 min. Cells were then washed three 155 
times with cold PBS and cultured in 200µl of fresh medium. The type-A CpG-2216-FITC (1 µg/ml) 156 
was also included as positive control. After 5 h incubation pDC were stained against CD4 and isotype 157 
specific Alexa 546 conjugate. Finally, the cells were fixed with the Fix & Perm kit and transferred in 158 
8-well Lab-Tek® chambers (Nunc, Wiesbaden, Germany). The slides were mounted with Moviol and 159 
analyzed by confocal microscopy (Leica TCS-SL confocal microscope and software; Leica 160 
Microsystems AG, Switzerland). All images were acquired using a 63× oil-immersion objective, with 161 
settings for high-resolution images acquired at optimum voxel size and automatic threshold. 162 
Bacterial culture and cytotoxic assay 163 
The ability of killing or inhibiting the growth of XL1-Blue E.coli was investigated for the scrambled 164 
peptide and PMAP-36 using adapted protocols (8, 24). All inoculums were harvested in mid-log phase 165 
growth of XL1-Blue E.coli and the CFU/ml was calculated with the OD600 value (0.3-0.6) from a 166 
previous known standard curve. To determine the killing activity of the peptides, 4x10-9 mol followed 167 
by 4-fold dilutions of scrambled peptide and PMAP-36 (final concentration of 40 µM, 10 µM, 2.5 µM 168 
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and 0.6 µM) were added in 50 µl of PBS in 96-microwell plate. A volume of 50 µl of PBS containing 169 
2x106 CFU was added to each peptide dilution to reach the above concentrations. Following 1 h 170 
incubation at 37°C, 10 µl from serial 10-fold dilutions were plated on agar to count the CFU. The 171 
experiments were performed in triplicates. 172 
The minimal inhibitory concentration of the scrambled peptide and PMAP-36 was determined as 173 
being the lowest peptide concentration where no bacterial growth was monitored by reading the 174 
OD600. Briefly, serial 2-fold dilutions starting by 90 µl of 10 µM of scrambled peptide or PMAP-36 175 
were inoculated with 10 µl of LB containing 106 CFU. Cultures were incubated at 37°C under 220 176 
rpm and absorbance was quantified by photospectrometry reading the OD600 at several time points. 177 
The experiments were performed in quadruplicates.  178 
Phylogenetic analysis 179 
Published sequences of the C-terminal mature form of cathelicidin were retrieved from Zanetti (1). 180 
The unrooted phylogenetic tree was constructed using the neighbour-joining method (p distance 181 
model) on the MEGA5 program. 182 
Software and statistical analysis 183 
Peptide helical projection and net charge were obtained on HeliQuest (http://heliquest.ipmc.cnrs.fr/). 184 
Confocal images were analyzed on IMARIS 7.6 software (Bitplane AG) to subtract threshold and 185 
gamma-correction compared to negative control such that no false-positive emissions could occur. 186 
Conformation of the scrambled peptide was predicted on PsiPred (http://bioinf.cs.ucl.ac.uk/psipred/) 187 
and Jpred (http://www.compbio.dundee.ac.uk/www-jpred/). Data were analyzed using GraphPad 188 
Prism 6.0 and multiple comparisons were considered using a One-way or Two-way ANOVA. 189 
Dunnett's multiple comparison post-hoc test was employed to compare data with a control group 190 
whilst Bonferroni was employed to compare all treatment groups. Significant differences are noted * 191 
(p<0.05), ** (p<0.01) or *** (p<0.001). 192 
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Results 193 
Porcine cathelicidins complex DNA with an efficacy relating to their cationic charge.  194 
Cathelicidins are usually subcategorized in different classes according to the highly diverse peptide 195 
conformations that can be observed in certain vertebrates. Phylogenetic analysis of the C-terminal part 196 
of several cathelicidin members showed at least two clusters including α-helical and prolin/arginine or 197 
cystein-rich peptides (Fig. 1A;  (1, 3)). Interestingly, each species expresses at least one cathelicidin 198 
peptide from the α-helical class. On the other hand, the closest porcine cathelicidin related to the 199 
human LL-37 was found to be PMAP-36. The pig possesses a wide range of structurally diverse 200 
cationic peptides, which could in theory interact with negatively charged molecules such as nucleic 201 
acids. However, except to their antimicrobial activity, nothing is known about their role and their 202 
interaction with innate immune cells. Therefore, we investigated the influence of three synthetic 203 
porcine cathelicidin members including two α-helical peptides, PMAP-36 and PMAP-23, and PR-39 204 
in delivering nucleic acid complexes to porcine pDC. The helical wheel projection of these synthetic 205 
peptides showed that both PMAP-23 and PMAP-36 share an amphipathic conformation but differ in 206 
their net charge, PMAP-36 being the most cationic (Fig. 1B). The cationic charge of PR-39 was found 207 
to be an intermediate between PMAP-23 and PMAP-36. A shift assay revealed that the synthetic 208 
peptides could complex a plasmid DNA through electrostatic interactions (Fig. 1C). As expected, a 209 
lower concentration of PMAP-36 was required to inhibit the migration of DNA compared to PR-39 210 
and PMAP-23. These results indicate that the three synthetic peptides interact and complex DNA with 211 
different efficacy, which closely relates to the cationic charge of the peptide. 212 
Cathelicidins promote nucleic acid-mediated secretion of IFN-α after short term incubation in pDC. 213 
We next examined whether complexes of nucleic acids with porcine cathelicidins could trigger a 214 
potent activation of porcine pDC. The synthetic peptides PR-39, PMAP-23 and PMAP-36 were 215 
incubated at RT with several types of nucleic acids including E.coli DNA, plasmid DNA, type-A CpG 216 
and poly(U). After 10 min incubation at RT, these complexes were exposed to enriched pDC for 10 217 
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min and then extensively washed and cultured for a further 20 h at 39°C. All three peptides complexed 218 
to E.coli DNA induced high levels of IFN-α whilst E.coli DNA alone following removal after 10 min, 219 
was unable to trigger IFN-α (Fig. 2A). The highest levels of IFN-α were observed with 40 µM for PR-220 
39 and PMAP-23 while 2.5 µM PMAP-36 induced the maximal response. These responses were even 221 
higher than those induced by E. coli DNA left in the cultures during the 20 h stimulation period (ctrl). 222 
When complexes of plasmid DNA with the three peptides were employed, it was again the PMAP-36, 223 
which was the most potent (Fig. 2B). Complexes of CpG with PR-39 and PMAP-36 also revealed a 224 
similar dose-response pattern (Fig. 2C). Complexes of poly(U), a synthetic RNA-like molecule, with 225 
PMAP-36 induced the highest levels of IFN-α, even higher than when complexed with DOTAP, a 226 
transfection reagent. Exposure of pDC to poly(U) alone did not induce IFN-α secretion (Fig. 2D). 227 
None of the cathelicidins tested alone induced IFN-α in enriched pDC (data not shown). Altogether, 228 
these data indicate that complexes of porcine cathelicidins with different types of nucleic acids were 229 
potent factors to induce IFN-α responses in enriched pDC. Such immune responses were the most 230 
efficient with PMAP-36 independently of the size and type of nucleic acids employed.  231 
To test if complexes of nucleic acids and cathelicidins enables a faster delivery into the cells, the 232 
association of E.coli DNA complexed to PMAP-36 with pDC was examined over time. As shown in 233 
Fig. 3A, the percentage of E.coli DNA+ pDC reached almost 80% after only 10 min of exposure and 234 
did not increase after 30 min incubation. Similar results were obtained with PMAP-23 and PR-39 235 
(Supplemental Fig. 1). These findings demonstrate that porcine cathelicidin enable a rapid interaction 236 
of nucleic acid molecules with pDC.  237 
We next investigated if the production of IFN-α was mainly mediated by pDC using intracellular 238 
cytokine staining. Enriched pDC were incubated with E.coli DNA complexed to PMAP-36 for 10 min 239 
and then were washed extensively. After an 8 h incubation, flow cytometry analysis revealed that only 240 
CD172lowCD4high pDC stimulated with CpG or E.coli DNA complexed to PMAP-36 showed IFN-α 241 
present inside the cells (Fig. 3B). No fluorescence signal was detected in the CD4- populations 242 
indicating that neither conventional blood dendritic cells nor monocytes were involved in this IFN-α 243 
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response. A kinetic assay of intracellular and secreted IFN-α was performed to characterize pDC 244 
responsiveness over time (Fig. 3C). Detectable amounts of IFN-α in the supernatants were already 245 
observed at 8 h post-stimulation when E.coli DNA was complexed to PMAP-36, whereas no IFN-α 246 
was observed in CpG-treated cells. Only minimal amounts of IFN-α were noted with E.coli DNA 247 
alone.  248 
To confirm that nucleic acids were internalized by pDC, the latter subset was purified by FACS 249 
sorting (Supplemental Fig. 2) and loaded with peptide DNA complexes. Examination by confocal 250 
microscopy revealed that E.coli DNA when added alone was undetectable in pDC, similarly to 251 
untreated cells (Fig. 4A and 4B). In pDC exposed to CpG-FITC or to E.coli DNA complexed to 252 
PMAP-23, a comparable punctual distribution of internalized DNA was observed (Fig. 4C and 4D). In 253 
contrast, PR-39 and PMAP-36 formed large complexes with the E.coli DNA localized at the surface 254 
and inside pDC (Fig. 4E and 4F).  255 
Since recognition of DNA delivered by LL-37 is recognized by TLR9 in human, depending on pH 256 
endosomal acidification (17, 23), the effect of chloroquine regarding its ability to inhibit IFN-α 257 
responses triggered by E.coli DNA complexed to cathelicidins was investigated. At all chloroquine 258 
concentrations, a complete inhibition of IFN-α was observed in enriched pDC stimulated with CpG or 259 
E.coli DNA complexed to PMAP-23, whereas the responses induced by E.coli DNA coupled with PR-260 
39 or PMAP-36 was only inhibited at high doses of chloroquine (Fig. 5). These data indicate that the 261 
induction of IFN-α in response to nucleic acid delivered by PR-39 and PMAP-36 is less sensitive to 262 
pH perturbation compared to the CpG-induced IFN-α responses in pDC. 263 
PMAP-36-mediated-killing is dependent on its amphipathic conformation enhancing the levels of IFN-264 
α responses to E.coli in enriched pDC. 265 
Considering the reported antimicrobial activity of porcine α-helical cathelicidins against several 266 
pathogens including Gram+ and Gram- bacteria (3), we investigated whether cathelicidins can mediate 267 
pDC activation by bacteria employing both, their bacteriolytic activity and their capacity to deliver 268 
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released bacterial DNA to pDC. To this end, we employed a scrambled version of PMAP-36 predicted 269 
to be incapable of forming an α-helix. Moreover, bioinformatical helical wheel projection 270 
demonstrated that the hydrophobic residues were no more allocated in a transversely amphipathic 271 
arrangement than the original peptide (Fig. 6A). As expected, the antimicrobial activity was reduced 272 
when comparing the scrambled peptide to PMAP-36, both in terms of bacterial killing (Fig. 6B) and 273 
bacterial growth inhibition (Fig 6C). At all concentrations employed to inhibit the growth, the 274 
scrambled peptide only delayed E.coli propagation, whilst 2.5 µM of PMAP-36 was already enough to 275 
completely abolish the bacterial growth. Nonetheless, the capacity of these peptides to form 276 
complexes with DNA and induce potent IFN-α responses in enriched pDC was similar, even more 277 
efficient at 10 µM for the scrambled counterpart (Fig. 6C). Altogether, these data indicate that the α-278 
helical amphipathic conformation of PMAP-36 displays a critical role in killing bacteria but is not 279 
essential to promote IFN-α responses in pDC. We next tested the effect of PMAP-36 on pDC 280 
stimulation by E. coli. To this end, the bacteria were incubated alone, with the scrambled peptide or 281 
PAMP-36 peptide for 1 h, afterwards enriched pDC were added. At 40 µM, PMAP-36 significantly 282 
enhanced IFN-α compared to its non-sense version (Fig. 7). The bacteria E. coli alone were unable to 283 
activate pDC. These data suggest that through its combined antimicrobial and DNA complexing 284 
activity, PMAP-36 can mediate pDC activation in response to bacteria.  285 
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Discussion 286 
Porcine cathelicidins represent a large group of structurally diverse HDP, including α-helical, 287 
prolin/arginin-rich and cystein-rich peptides. In contrast, LL-37 representing an α-helical peptide is the 288 
only known human cathelicidin. Instead, much more members of the defensin family are found in 289 
human (3). Interestingly, phylogenic analyses of the C-terminal bioactive form of cathelicidins from 290 
several vertebrates revealed that the PMAP-36 clusters closely with the human LL-37, suggesting a 291 
certain homology in the functionality of these peptides. In addition to its bactericidal activity (25, 26), 292 
LL-37 contributes to many other immune functions including neutralization of LPS (27), chemotaxis 293 
of cells (28), regulation of macrophage differentiation (29) and activation (30, 31). In the study of 294 
Hurtado and Peh, it was shown that this cationic peptide contributes to a rapid sensing of CpG in B 295 
cells and pDC (16). With the results obtained from the phylogenic analysis and the stimulation of 296 
porcine pDC, it is possible to consider PMAP-36 as the functional homolog of the human LL-37. In 297 
accordance with the observations in human (16), the sensing of nucleic acids delivered by PMAP-36 298 
to pDC is also independent on its amphipathic configuration or its microbicidal properties. One can 299 
propose that the range of action of PMAP-36 and some of other porcine cathelicidin members might 300 
certainly be broader than only mediating killing of bacteria and sensing of nucleic acids by pDC. 301 
Observations such as these invite further investigations to decipher the interactions of porcine 302 
cathelicidins with other immune cells. 303 
The ability of pDC to sense CpG motifs, has mainly been attributed to the expression of TLR9 that 304 
decorates their endosomal compartments (32). In humans, it was demonstrated that induction of IFN-α 305 
by self-DNA complexed with LL-37, is dependent on TLR9 recognition , a feature of certain 306 
autoimmune diseases (17, 18). Similarly, self-RNA complexed to LL-37 also triggered IFN-α in pDC 307 
through TLR7-mediated pathway (33). Although TLR9 was shown to be critical for the recognition of 308 
microbial DNA, a recent report demonstrated the presence of cytosolic aspartate-glutamate-any amino 309 
acid-aspartate/histidine (DExD/H)-box helicases, DHX36 and DHX9, which were able to bind to 310 
CpG. These receptors signal through MyD88 (34). The fact that CpG-induced IFN-α is abolished by 311 
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the presence of chloroquine is attributed to perturbations of endosomal and lysomosal pH (23). The 312 
recognition of type-A CpG is well characterized and mainly signals through TLR9 in the endosome 313 
(35). Therefore, the weak chloroquine-mediated inhibition of IFN-α responses to E.coli DNA 314 
complexed to PR-39 and PMAP-36 could indicate that receptors other than TLR9 are involve in such 315 
responses. Unfortunately, porcine TLR9 antagonist is not yet available to assess the contribution of 316 
this receptor. 317 
 The enhancement of IFN-α observed in response to whole bacteria might be explained by the rapid 318 
sensing of newly released DNA and RNA molecules from PMAP-36-mediated lysis of bacteria, which 319 
in turn are complexed to the cathelicidin. The observation that high concentrations of PMAP-36 were 320 
required to kill bacteria and form stimulatory nucleic acids complexes, may be explained by the 321 
association of the peptides bacterial membranes, and the possible presence of inhibitory factors for 322 
pDC activation. Nevertheless, we propose a model in which cathelicidins secreted by neutrophils 323 
would act in tandem with pDC to promote IFN-α induction, favoring a microenvironment suitable for 324 
an efficient adaptive immune response. In addition to their antiviral effect, type I IFNs have been 325 
shown to promote Th1 response in human (36), and antigen cross-presentation by dendritic cells (37), 326 
as well as stimulating antibody production and isotype class switching in B cells (38). Moreover, the 327 
signaling of type I IFNs was associated to host resistance against group B streptococci, pneumococci, 328 
and E. coli (39) underlining the important role of type I IFN in bacterial infections. Another important 329 
aspect regarding cathelicidin might be their use in vaccine formulation to deliver nucleic acids to PRR 330 
(40). However, exposure to excessive levels of cathelicidin can have deleterious effects during the 331 
development of an immune response (41). In this respect, we found an inhibition of IFN-α production 332 
at the highest PMAP-36 concentration employed, indicating that cathelicidins can also impair the 333 
recognition of nucleic acids by PRR. In vivo studies questioning the efficiency of cathelicidin-334 
formulated vaccine are required to determine their potential in improving vaccine formulations. 335 
In conclusion, this study demonstrates that three porcine cathelicidins efficiently complex nucleic 336 
acids for delivery to pDC resulting in potent IFN-α release. In contrast to the antimicrobial activity of 337 
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these peptides, this was only related to the net charge of the peptide. With this dual function, we have 338 
demonstrated that the peptide PMAP-36 can promote pDC activation in response to E.coli. 339 
Collectively, the present data confirm the remarkable link between cathelicidins and IFN-α release by 340 
pDC also for the porcine immune system, which could be of significance during viral-bacterial co-341 
infections. 342 
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Figure legends 485 
Figure 1. Porcine cathelicidins complex nucleic acids with different efficacy relating to their 486 
cationic charge. (A) Unrooted phylogenetic tree of the C-terminal active form of cathelicidin in 487 
mammals including human (LL-37), rhesus monkey (RL-37), rabbit (CAP18), mouse (CRAMP), Rat 488 
(rCRAMP), dog (canine cath), horse (eCATH-1, eCATH-2 and eCATH-3), cow (Bac5, Bac7, BMAP-489 
27, BMAP-34, Indolicidin and Dodecapeptide), sheep (OADode, SMAP-29, SMAP-34, OaBac5, 490 
OaBac6 OaBac7.5 and OaBac11) and pig (PR-39, Prophenin-1, Prophenin-2, PMAP-23, PMAP-36, 491 
PMAP-37,PG-1, PG-2, PG-3, PG-4 and PG-5) is shown. The tree was constructed using the neighbor-492 
joining method  (p distance model). The putative clade of α-helical peptides is encircled. (B) Helical 493 
wheel projection of PR-39, PMAP-23 and PMAP-36 are presented. The hydrophobic residues are 494 
displayed in yellow, the N- and C-terminal parts of the peptide are noted N and C in red, respectively. 495 
Analyses of the net charge and the helical projections were determined with HeliQuest 496 
(http://heliquest.ipmc.cnrs.fr/). (C) PR-39, PMAP-23 and PMAP-36 complex nucleic acid with 497 
different efficacy. Serial dilutions of PR-39, PMAP-23 and PMAP-36 were mixed with 250 ng of 498 
plasmid DNA in PBS for 10 min. The mixtures were run on 0.8% gel agarose gel and DNA was 499 
visualized with ethidium bromide under UV radiation. 500 
Figure 2. Cathelicidins enable nucleic acids-mediated pDC activation after short term 501 
incubation. E.coli DNA (10 µg/ml) (A), plasmid DNA (10 µg/ml) (B), CpG (2.5 µg/ml) (C) or 502 
poly(U) (10 µg/ml) (D) were complexed with PR-39, PMAP-23 or PMAP-36 for 10 min before being 503 
added to enriched pDC. Cells were then extensively washed with cold PBS and cultured for 20 h. An 504 
incubation of 20 h without washing the cells was used as positive control (ctrl). Since poly(U) poorly 505 
induced IFN-α even after 20 h incubation, DOTAP incubated for 10 min (DOTAP) or 20 h (DOTAP 506 
ctrl) was used to confirm that cells were responsive (D). Secreted IFN-α was quantified by ELISA. 507 
Bars show the mean ± SD of triplicate. Significance compared to the absence of peptide was denoted * 508 
(p<0.05), ** (p<0.01) or *** (p<0.001) following Dunnett's multiple comparison test. All data have 509 
been reproduced at least two times in independent experiments. 510 
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Figure 3. PMAP-36 enables a rapid association of E.coli DNA to trigger IFN-α response in pDC. 511 
(A) Flow cytometry demonstrated a rapid association of E.coli DNA with pDC. E.coli DNA labeled 512 
with FITC (at 10µg/ml) was complexed to PMAP-36 (final concentration 2.5 µM) for 10 min at RT. 513 
Enriched pDC were added and incubated at 39°C for 1, 5, 10 and 30 min. Cells were washed and 514 
stained against CD172a and CD4 to identify pDC. Representative figures are shown (B) Intracellular 515 
IFN-α was only associated with CD172lowCD4high pDC. Enriched pDC were incubated either with 516 
E.coli DNA, CpG or E.coli DNA complexed to PMAP-36 for 10 min or left untreated. Cells were 517 
washed extensively and cultured for a further 8 h. Pseudo-color plot of pDC defined as 518 
CD172lowCD4high and CD172+CD4- populations are gated (left panel) and contour plots demonstrate 519 
that only the subsets of pDC are positive for intracellular IFN-α (right panel) after E.coli DNA 520 
complexed to PMAP-36 or CpG stimulation. Gate frequency is indicated as mean ± SD of duplicate. 521 
One out of two independent experiments is shown. (C) Kinetics of intracellular and secreted IFN-α in 522 
pDC revealed a peak of production after 8-10 h post-stimulation. The Amount of IFN-α detected in the 523 
supernatants (left axis; dotted lines) and percentage of IFN-α+ pDC (right axis; open bars) is shown. 524 
One representative out of two independent experiments is shown. 525 
Figure 4. Complexes of E.coli DNA with cathelicidins and their association with pDC. (A, B, D-526 
F) E.coli DNA labeled with Alexa 488 (10 µg/ml) was complexed to PR-39, PMAP-23 (40 µM) and 527 
PMAP-36 (2.5 µM) for 10 min at RT or left untreated. Afterwards, 1x105 pure pDC were added for 10 528 
min. Cells were then extensively washed and incubated in fresh medium at 39°C for 5h. (C) CpG 529 
2216-FITC (1 µg/ml) was employed as positive control. Cells were then stained against membrane 530 
CD4 (in red) and were finally fixed. The presence of E.coli DNA or CpG is shown in green. Bars 531 
represent 10 µm. Representative pictures, observed in three independent experiments, are shown. 532 
Figure 5. IFN-α responses to E.coli DNA complexed to PMAP-36 and PR-39 are relatively 533 
resistant to inhibition endosomal acidification. Complexes of E.coli DNA (10 µg/ml) with PR-39, 534 
PMAP-23 (40 µM) or PMAP-36 (2.5µM) for 10 min were added to enriched pDC pretreated with 535 
increasing amount of chloroquine. Cells were then extensively washed with cold PBS and cultured for 536 
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20 h. Cells treated with CpG were employed as positive control. The relative inhibition compared to 537 
untreated cells was calculated as following: 100-(simulated cells)/(stimulated cells+chloroquine)x100. 538 
Data are representative of two independent experiment. Significance compared to the chloroquine-539 
mediated inhibition of CpG-induced IFN-α is denoted by ** (p<0.01) and *** (p<0.001) following a 540 
Two-way ANOVA and Bonferroni post-tests. 541 
Figure 6. The amphipathic conformation of PMAP-36 plays a crucial role in antimicrobial 542 
activity but not in delivering nucleic acids to pDC. (A) The random sequence of PMAP-36 543 
(scrambled) is shown by an helical wheel projection. Hydrophobic residues are displayed in yellow, 544 
the N- and C-terminus parts of the peptide are noted N and C in red, respectively. (B-C) PMAP-36 is 545 
more efficient at killing or inhibiting the growth of E.coli than its scrambled counterpart. (B) Different 546 
concentrations of scrambled peptide and PMAP-36 peptides were incubated with 2x106 CFU for 1 h in 547 
PBS. Serial 10-fold dilution were then plated on agar to count colonies and data were expressed in 548 
CFU/ml. Data show the mean ± SD of culture triplicates and are representative of three independent 549 
experiments. Significance is indicated by *** (p<0.001) following a Two-way ANOVA and 550 
Bonferroni post-hoc tests. (C) Several 2-fold dilutions of scrambled peptide and PMAP-36 were 551 
incubated with 1x106 CFU in LB medium at 37°C for 1 to 8 and 24 h. The growth of E.coli was 552 
determined by reading the absorbance (OD600). Data show the mean ± SD of culture quadruplicates 553 
and are representative of three independent experiments. (D) A similar dose response of E.coli DNA-554 
induced IFN-α is observed for the scrambled peptide and PMAP-36 in enriched pDC. E.coli DNA 555 
(10µg/ml) was complexed to scrambled peptide or PMAP-36 for 10 min before addition to enriched 556 
pDC. Cells were then extensively washed with cold PBS and cultured for 20 h. Secreted IFN-α was 557 
quantified by ELISA. Bars show the mean ± SD of triplicate. Data are representative of three 558 
independent experiments. Significance is denoted by *** (p<0.001) following a Two-way ANOVA 559 
and Bonferroni post-tests. 560 
Figure 7. PMAP-36 enhances the levels of IFN-α responses to E.coli in enriched pDC. A total of 561 
2x106 E.coli were incubated with 40 µM of scrambled peptide or PMAP-36 in FBS free DMEM. After 562 
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1 h, 4x105 enriched pDC were added and incubated in medium containing 1X Pen/strep and 10% FBS 563 
for 20 h. The levels of IFN-α were quantified by ELISA in cell-free supernatants. Each color represent 564 
an independent experiment performed in triplicate. The lines show the mean. One-way repeated 565 
measures ANOVA and Bonferroni post-tests were employed and significance between groups is 566 
denoted by ** (p<0.01) or *** (p<0.001). 567 
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Supplementary figure 1. Rapid association of E.coli DNA coupled to PMAP-23 and PR-
39 with pDC. Flow cytometry demonstrated a rapid association of E.coli DNA with pDC. 
E.coli DNA labeled with FITC (final concentration 10µg/ml) was complexed to PR-39 or 
PMAP-23 (final concentration 40 µM) for 10 min at room temperature. Enriched pDC were 
added and incubated at 39°C for 1, 5, 10 and 30 min. Cells were washed and stained against 
CD172 and CD4 to identify pDC. One out of three independent experiment is shown. 
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Supplementary figure 2. Purity of pDC was examined after FACS sorting procedure. 
CD172a-enriched cells were purify by electrostatic sorting based on a gate on 
CD172
low
CD4
high
 population using a FACSAria Cell Sorter. Left panel shows the purity of 
CD172a-enriched cell whereas right panel represent pure pDC population after the sorting 
procedure. 
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7. Discussion and Perspectives 
PCV2 is associated with immunosuppression resulting in increased host susceptibility to disease 
progression and secondary infections [91, 100, 101]. Although PCV2 DNA has been described to 
inhibit pDC function, our work provides evidence that PCV2 can have both stimulatory and inhibitory 
properties regarding the induction of type I IFNs by pDCs. These findings confirm earlier studies 
performed by others showing that different motifs of synthetic CpG-ODN sequences derived from the 
PCV2 genome could differentially modulate IFN-α responses in porcine PBMCs [140-142]. We 
demonstrated that PCV2 is able to induce IFN-α in an IFN-γ-dependent process in pDCs. We also 
found that using DNase treatment, the secretion of IFN-α was not altered indicating that the 
stimulation properties of PCV2 can be attributed to the encapsulated genomic ssDNA. However, we 
cannot exclude the participation of the capsid itself in the release of IFN-α by pDCs. We proposed that 
pDCs might be the early original source of type I IFNs in pigs infected by PCV2 since few reports 
detected IFN-α in the serum of animals after PCV2 challenge [143, 144]. 
In contrast to a previous publication where PRRSV-2 was assigned as potent antagonist of type I IFN 
responses in pDCs, we demonstrate that neither genotype 1 nor 2 PRRSV isolates strongly inhibit 
CpG-ODN induced IFN-α by pDCs. The highest level of inhibition (51%) was reached by a Chinese 
isolate but was not as suppressive as PCV2 in our parallel study (82% inhibition). Additionally, we 
observed that all PRRSV isolates tested could induce IFN-α secretion by pDCs, a response which was 
triggered through TLR7 signaling pathway. Similarly to PCV2 infection, we hypothesize that systemic 
IFN-α detected in PRRSV infected pigs might originate from pDCs [193, 209, 210]. Furthermore, we 
found that PRRSV-induced IFN-α secretion by pDCs protected permissive MoDC from PRRSV 
infection. These data confirm previous reports indicating that PRRSV is sensitive to the effect of type I 
IFNs [184, 198, 199] and might be potent factor to limit viral replication during early steps of an 
immune response. 
Interestingly, the levels of IFN-α induced by both PCV2 and PRRSV can be significantly increased by 
the presence of IFN-γ. Moreover, similar effects were observed in pDCs stimulated with FMDV [74]. 
These data suggest that IFN-γ could play an indirect role in viral sensing by the innate immune 
system. It is well known that type I IFNs promote NK cell activation which is required for the 
secretion of IFN-γ and cytotoxic activity. Altogether, it seems that a cytokine-mediated bidirectional 
crosstalk exists between NK cells and pDCs [250], which could be of importance in early control of 
virus infections. 
In pig, the functional and phenotypic characteristics of M1 and M2 MΦ have not been clarified yet. 
We demonstrated that the polarization of MDM into M1-like-MΦ by IFN-γ or IFN-β-activated MΦ 
enables the distinction of PRRSV isolates based on the genotype and more importantly on their 
virulence. Such an in vitro model will be helpful for investigating important viral elements relating to 
virulence, or alternately, for the identification of efficient defense mechanisms against PRRSV. For 
instance, transcriptomic tools will help to identify genes involved in the inhibition of PRRSV 
replication in relevant host cells. 
In our last study, we showed that porcine cathelicidins were potent factors to mediate a rapid uptake of 
nucleic acids resulting in a consequent IFN-α secretion by pDCs. Furthermore, we hypothesized that a 
certain homologies in the functions are shared between PMAP-36 and the human LL-37 [226]. 
Consequently, PMAP-36 as well as other porcine cathelicidins could potentially impact on anti-
microbial immune responses by modulating cellular functions. We also proposed that cathelicidin-
mediated killing of bacteria followed by the induction of pDC-derived IFN-α is relevant in vivo to 
mount an efficient adaptive immune response upon bacterial infection. Nonetheless, we attempted to 
compare the efficacy between ex vivo-derived and synthetic cathelicidins in order to confirm this 
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mechanism previously observed in vitro. Neutrophils are important players of innate immunity 
promoting neutrophils extracellular traps (NETs) [251]. It has been shown that neutrophil-mediated 
killing of bacteria happens at both intracellular and extracellular interfaces [252, 253]. Scapinello and 
colleagues reported that porcine neutrophil secretions have strong bactericidal activity. Mass 
spectrometry analysis revealed that among many secreted proteins, PMAP-36 and lactotransferrin are 
upregulated by phorbol 12-mistrate 13-acetate (PMA) in neutrophils. Thus, the antimicrobial activity 
of neutrophil secretions could be in part attributed to these two identified proteins, which are known to 
have antibacterial effects in vitro [238, 254]. In our hand, whilst preparations of PMA-stimulated 
neutrophil supernatants inhibited DNA migration in a gel-shift assay, they did not increase pDC-
derived IFN-α in response to E.coli DNA compared to supernatants of unactivated neutrophils. 
However, both PMA- and unstimulated neutrophil supernatants tended to promote higher levels of 
IFN-α than a stimulation with E.coli DNA alone but were not as potent as the synthetic peptides. 
These observations might be explained by the presence of inhibitory factors for pDC responsiveness. 
Another aspect, which interferes with the secretion of IFN-α by pDCs, would be the PMA, since it was 
found to abrogate CpG-induced IFN-α responses in our model. Even though neutrophil secretions 
partly increased IFN-α responses by pDCs, we were not able to confirm that such responses are 
attributed to ex vivo-derived cathelicidins. In this respect, a close examination implying purification 
steps of these secretion content might corroborate the results observed with the synthetic cathelicidins. 
Certain  DNA motifs of PCV2 genome have been described to modulate the cytokine production  in 
PBMCs [140-142]. Our reports strongly suggest that the free dsDNA replicative intermediates of 
PCV2 are responsible for the suppression of pDC responsiveness in vitro, while encapsulated genomic 
ssDNA is stimulatory. Interestingly, dsDNA replicative forms have been detected in lymphoid tissues 
of PMWS-suffering pigs [97, 139]. On the other hand, it seems that the activation of the immune 
system represent a crucial event to induce PMWS development [82]. During the course of an immune 
response, it might be correct to think that the cathelicidins might be upregulated and released by 
several innate immune cells [255]. Thus, cathelicidin would play an important role in delivering the 
inhibitory dsDNA forms of PCV2 into immune cells leaving the host susceptible to disease 
development. This idea is supported by the fact that most of the pigs infected by PCV2 alone are 
asymptomatic and the reproduction of PMWS has only been achieved in coinfection models with other 
pathogens [81, 94, 102-106]. 
Another important aspect which could be further investigated, is the influence of cathelicidins in cell 
development, especially MΦ. In the study of van der Does et al., it has been demonstrated that anti-
inflammatory M2 MΦ cultured with LL-37 demonstrate a pro-inflammatory signature characterized 
by a low expression of CD163 and poor secretion of IL-10 after LPS stimulation [242]. These findings 
could be translated to the porcine model suggesting that the expression of important receptors or 
cellular factors implicated in PRRSV immunobiology could be altered by the presence of 
cathelicidins. Accordingly, the levels of two cathelicidins, PR-39 and prophenine-2, as well as the 
number of PMNC in the bronchoalveolar lavages were shown to increase in the lungs of pigs 
following challenge with Actinobacillus pleuropneumoniae [256]. Due to the increased susceptibility 
to other pathogens in the lungs of PRRSV-infected pigs and persistence of the virus [166], it could be 
considered that some important factors must impair the clearance of the virus by immune cells. In this 
respect, cathelicidins could be involved in the resistance of the virus by modulating the differentiation 
of monocytic cells and MΦ activation. It therefore could be attractive to evaluate the impact of porcine 
cathelicidins on MΦ differentiation and their susceptibility to PRRSV. In our hand, M2-activated MΦ 
show a down-regulation of CD163 but were still highly inclined to infection. A combination of certain 
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activation stages of MΦ as well as immunomodulating factors such cathelicidins might contribute to 
the puzzling PRRS pathogenesis. 
In conclusion, we demonstrated that pDCs can induce IFN-α in response to two known 
immunosuppressive viruses, PCV2 and PRRSV. These data suggest that pDCs might be the source of 
IFN-α in vivo. Additionally, we showed that porcine cathelicidins represent important factors involved 
the type I IFN induction by pDCs at least in vitro. These recent findings indicating that cathelicidin 
peptides display multiple functions should be implicated in concepts explaining the immunobiology of 
viral and bacterial co-infections. 
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